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I':enal function is a key factor in the long term control of blood pressure. 
The kidney has a large capacity to synthesise. a.number of prostaglandins, particularly 
PGE and PGI . These compounds are systemic vasodilators and when infused . 
into the kidney cause renal vasodi.latation,renin release and'an'increase in sodium 
t xcretion. By virtue of these potential actions they may, therefore, have án 
important role in the control of renal functi_on..and ultimately in the longterm 
control of blood pressure. In this: thesis. the. results of a.number. of studies in 
both animals and man are described which aim to clarify the importance of 
prostaglandins as determinants of renal function. Both radi.oimmunoassay 
.1nd gas chromatography - mass spectrometric methods for measuring prostaglandins 
and their metabolites were developed. 
These methods were then employed to determine the effect of changes in sodium balance 
on renal PGE synthesis in conscious dogs during the development of one clip -two 
kidney hypertension. Sodium balance was manipulated during the early phase 
of this process by the controlled removal of salt and water using haemofiltration. 
interrelationship between prostaglandins and the renin- angiotensin system was 
explored in a series of experiments; firstly by measuring changes in systemic PGI2 
synthesis in conscious dogs during infusion of angiotensin II and secondly by 
measuring changes in renal haemodynamics, sodium excretion and PGE excretion in 
response to infusion of different doses of angiotensin II before and after the 
development of one clip -two kidney hypertension. In view of the importance of 
renal interstitial cells as a source of prostaglandins, changes in'thei.r morphology 
was also studied in normotensive and hypertensive dogs. 
The second part of the thesis concentrates on studies in man. The effect of 
rapid expansion of the extracellular fluid volume on renal PGE and systemic PGI2 
synthesis was examined. Systemic PGI synthesis -was measured during varying 
levels of activity of the renin-angiotensin system, induced'by changes,in 
dietary sodium intake and also by comparing synthesis. beforé and after removal 
of an aidosterone secreting adenoma from patients'.. 
The res -alts support the hypothesis that renal PCE synthesis is important.in maintaining 
renal blood floe in the presence of vasoconstrictor stimuli.Such as :angiotensin II. 
c rclr f changes it renal PGE synthesis during the development of renal ' 
hypertension is less clear but the results are consistent with the hypothesis 
that PGE may serve as an intrarenal natriureti.c' agent. Systemic PGI2. 
synthesis does not appear to be of importance in modulating :the systemic vas'o - 
constrictor effects of angiotensin II. The observation of relative increases in its 
synthesis during period of high sodium intake, immediately after a rapid intravenous 
infusion of sodium chloride and in the presence of hyperaldosteronism 
'ire all consistent with the concept that changes in vascular filling pressure may 
De modulated by changes in systemic PGI2 synthesis. 
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INTRODUCTION 
1. GENERAL CONSIDERATION 
In experimental animal models and in man the 
transition from normotension to hypertension is a 
complex process characterised by, amongst other things, 
changes in cardiac output, total peripheral resistance 
and renal function. The relative importance of these 
these variables in the transition remains 
controversial. One theory that attempts to integrate 
all the known factors, and may also account for 
some that are still unknown, is that of whole body 
autoregulation. First proposed by Ledingham and Cohen 
(1964) and expanded upon by Guyton, Coleman, Cowley, 
Scheel, Manning and Norman, (1972), the theory proposes 
that the rise in blood pressure that occurs during the 
development of hypertension is mediated entirely through 
a rise in cardiac output. This is believed to trigger a 
myogenic response in the resistance vessels producing an 
'autoregulatory' rise in total peripheral resistance 
which eventually leads to a restoration of normal 
cardiac output. An additional feature of the theory 
which has been emphasised by others (Kaplan 1979), 
is the pre- eminent role of the kidney in this process. 
Blood pressure cannot be persistently elevated over a 
long period of time without the occurrence of some 
adaptation of renal function. Any acute elevation in 
blood pressure will result in sustained natriuresis, 
followed by a decrease in extracellular fluid volume 
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and cardiac output, and a restoration of normotension. 
The proposed adaptation of the kidney in established 
hypertension involves resetting of the natriuretic 
response to increased blood pressure such that 
diminished natriuresis occurs and the hypertension 
persists. 
This is envisaged to be an 'infinite gain' long term 
effect, and therefore assigns a critical role to the 
kidney in any theory accounting for long term blood 
pressure elevation. 
The theory naturally arouses much controversy, 
perhaps fueled by its heavy reliance on theoretical 
aspects of control systems, and the expression of these 
concepts in terms of engineering principles. Supportive 
experimental evidence for the occurrence of long term 
autoregulaton is limited and has been criticised as 
inadequate (Korner 1980). The pre- eminent role assigned 
to the kidney for the long term control of blood 
pressure has more general support and has led to much 
work aimed at determining the mechanism controlling 
renal sodium excretion. 
2. CONTROL OF SODIUM EXCRETION 
There are numerous postulated mechanisms for the 
control of sodium excretion but this introduction 
particularly explores those mechanisms in which 
prostaglandins and the renin angiotensin system may 
participate directly. The mechanisms may best be 
divided into those primarily operating through changes 
in vascular tone, and those directly affecting tubular 
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function. 
Renal blood flow and glomerular filtration rate are 
the basic physical determinants of sodium excretion. 
The glomerular filtration rate of a single nephron 
(SNGFR) maybe expressed as:- 
SNGFR = Kf (P -II) 
Kf = ultrafiltration coefficient 
Kf = KxS 
K = effective hydraulic permeability of capillary wall 
S = total surface area for filtration 
P - II = net driving force for filtration 
ie. the difference between 
hydraulic and oncotic presssures. 
The hydraulic pressure difference across the 
glomerulus is determined by afferent and efferent 
arteriolar tone. Thus increased renal blood flow, if 
accompanied by no change in either afferent or efferent 
arteriolar tone, will not change glomerular filtration 
rate. Renal blood flow and efferent arteriole tone are 
together the important determinants of peritubular 
capillary hydraulic pressure. Under most circumstances 
there is a large drop in hydraulic pressure between the 
glomerular capillary circulation and the peritubular 
capillaries at the end of the efferent arteriole. 
Peritubular capillary oncotic pressure usually exceeds 
the hydraulic pressure and there is therefore a net 
force for fluid reabsorption from the adjacent proximal 
tubule. Increased renal blood flow without change in 
efferent arteriolar tone may increase peritubular 
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hydraulic pressure, thereby reducing the drive for fluid 
reabsorption from the proximal tubule. On the other 
hand, unchanged or increased renal blood flow with an 
increase in efferent arteriole tone will result in 
increased hydraulic driving force for glomerular 
filtration. Changes in physical structure of the 
glomerulus may also change the ultrafiltraton 
coefficient and thus result in changes in glomerular 
filtration rate. 
Activity of the renin angiotensin system is an 
important determinant of glomerular afferent and 
particularly efferent arteriolar tone (Myers, Deen and 
Brenner 1975; Brenner 1980). However there also appears 
to be an effect of angiotensin II on mesangial cell 
tone, perhaps via interference with transmembrane 
calcium transport (Ichikawa, Miele and Brenner 1979). 
Such an effect could well result in dramatic changes in 
glomerular capillary surface area available for 
ultrafiltration and therefore in Kf. Despite the renal 
vasodilator activity of prostaglandin E2, D2 and I2 
(Friesinger, Oelz, Sweetman, Nies and Data 1978; Jones, 
Watson and Ungar 1981) they only have a marginal effect 
on glomerular filtration rate when infused into the 
kidney, since under these conditions they produce equal 
effects on both afferent and efferent vessels, or a 
dominant effect on the efferent vessel (Baylis, Deen, 
Myers and Brenner 1976). However prostaglandins are 
synthesised by mesangial cells, glomerular epithelial 
cells and afferent and efferent arterioles (see later) 
and are therefore well placed to modulate locally 
glomerular filtration rate, renal blood flow and 
therefore proximal tubular sodium reabsorption. 
Distribution of blood flow within the kidney varies 
under different conditions. Evidence is accummulating 
that nephrons in outer and inner cortex vary 
considerably in their capacity to excrete sodium and 
water, partly by virtue of different filtration rates 
and length of tubules in nephrons from different sites 
(Horster and Thurau 1968). In the rat expansion of 
extracellular fluid volume results in greater delivery 
of sodium out of juxtamedullary nephrons, suggesting 
that these nephrons differ significantly from those in 
the outer cortex in their response to volume expansion 
(Stein, Osgood and Kunau 1976). There is evidence in 
favour of prostaglandins having a role in 
increasing blood flow preferentially towards these inner 
cortical nephrons (Kirschenbaum, White, Stein and Ferris 
1974; Chang, Splawinski, Oates and Nies, 1975), thus 
providing an alternative mechanism by which 
prostalgandins may promote sodium excretion. 
Direct effects of hormones on tubular sodium 
reabsorption seems an obvious means of controlling 
sodium excretion. Definitive evidence on involvement of 
particular hormones has not been easy to obtain since 
direct micropuncture methods are the only useful 
techniques. The role of aldosterone as a determinant of 
distal tubular sodium transport is most clearly 
established (Schwartz and Burg 1978). Angiotensin II 
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also probably has a direct effect on proximal tubular 
sodium transport. The effect observed on the isolated 
proximal tubules is dose dependent but at concentrations 
liable to occur in the kidney it is most likely to 
inhibit tubular sodium reabsorption (Harris and Young 
1977; Schuster, Kokko and Jacobson, 1984). Direct 
effects of prostaglandins on tubular sodium transport 
have also been reported (see later). 
Many factors other than prostaglandins and the renin 
angiotensin system have been invoked as determinants of 
renal haemodynamics and sodium excretion and therefore 
by implication in controlling systemic blood pressure. 
However there is also an entirely separate mechanism by 
which the kidney, independent of its capacity to excrete 
sodium, may lower blood pressure. 
3. ANTIHYPERTENSIVE FUNCTION OF THE KIDNEY 
Goldblatt first reported in 1934 that partial 
occlusion of one renal artery with the opposite kidney 
remaining intact, led to modest elevation of blood 
pressure (Goldblatt, Lynch, Hanzal and Summerville 1934) 
(1 clip - 2 kidney model of hypertension). 
Later it was demonstrated that much more severe 
hypertension followed if one renal artery was partially 
occluded and the contralateral kidney was removed 
(Goldblatt 1938). The contralateral kidney was 
apparently exerting antihypertensive activity. At first 
sight it might be assumed that this was a result of 
impaired renal excretory function after removal of the 
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contralateral kidney. In 1949 it was clearly 
established that the antihypertensive effect is 
independent of renal excretory function, but likely to 
be due to a blood born secretion from the kidney 
(Grollman, Muirhead, Vanatta 1949). Production of the 
factor is localised in the renal medulla (Lee, Covino, 
Takman and Smith 1965), indeed its effect can be 
mimicked in hypertensive rabbits by injection of 
cultured medullary interstitial cells (Muirhead, Brooks, 
Pitcock and Stephenson, 1972). In view of the known 
capacity of interstitial cells to synthesise 
prostaglandins it was thought that these might be the 
responsible hypotensive agents (Muirhead, Germain, 
Leach, Pitcock, Stephenson, Brooks, Brosius, Daniels and 
Hermain 1972). PGA, although subsequently shown to be 
an artifact, appeared at one time to be a particularly 
likely candidate (Lee, Covino, Takman and Smith 1965). 
It now seems most likely that the antihypertensive 
compound is a glyceryl ether derivative (Muirhead, 
Byers, Desiderio, Brooks and Brosius 1981). The 
interstitial cells are intimately associated with vasa 
rectae, collecting ducts and loops of Henle and are 
therefore well placed to influence tubular functions. 
Although prostaglandins do not function as circulating 
antihypertensive agents, several of them are potent 
vasodilators and may also have direct effects on renal 
tubular function (see later). Once synthesised in these 
cells they are well placed to exert effects on sodium 
and water excretion, and 
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therefore on blood 
pressure. 
Many studies have commented on the presence of dark 
osmiophilic granules in the interstitial cells (Osvaldo 
and Latta 1966), and it has been demonstrated that the 
number of such granules per interstitial cell is altered 
under a variety of different conditions of sodium 
balance and blood pressure (Nissen 1968; Tobian, Ishii 
and Duke 1969; Pitcock, Brown, Byers, Brooks and Brosius 
1981). The relationship of these granules to 
prostaglandin synthesis by the cells is unclear. Part 
of this thesis presents results of a study in dogs that 
aims to clarify this point, and relate it to the 
possible antihypertensive role of these cells. 
The 1 clip - 2 kidney model of hypertension in the 
dog, described by Goldblatt in 1934, has proven to be a 
useful experimental model for investigating both the 
mechanisms by which the kidney may increase blood 
pressure, and the mechanism by which it serves to 
ameliorate increases in blood pressure. 
The mechanism responsible for sustained elevation 
of blood pressure in this model is complex. The cause 
of the initial rise in pressure after partial occlusion 
of a renal artery is increased release of renin from the 
clamped kidney. The increased renin stimulates 
formation of angiotensin II. The rise in plasma 
concentration of angiotensin II is sufficient to 
account entirely for the rise in blood pressure 
(Caravaggi, Bianchi, Brown, Lever, Morton, Powell - 
Jackson, Robertson and Semple 1976; Freeman, Davis, 
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Watkins and Lohmeir 1977). Within a few days of partial 
constriction of the renal artery, plasma renin activity 
returns towards normal, but the blood pressure remains 
elevated ie. established hypertension develops 
(Bianchi, Baldoli, Lucca and Barbin, 1972; Watkins, 
Davis, Hanson, Lohmeir and Freeman, 1976; Lupu, Maxwell 
and Kaufman 1977; Maxwell, Lupu, Viskoper, Aravena and 
Waks 1977). 
During the renin dependent phase of 1 clip - 2 kidney 
hypertension,there is a transient modest retention of 
water (Bianchi, Baldoli, Lucca and Barbin 1972) and 
probably sodium (Watkins, Davis, Hanson, Lohmeir and 
Freeman 1976; Maxwell, Lupu, Viskoper, Aravena and Waks 
1977). Although subsequent excretion of the retained 
salt and water appears to be temporarily related to the 
decline in plasma renin activity, evidence for the 
importance of this retained salt and water in the 
progression to established hypertension in such a model 
is lacking. In the 1 clip - 1 kidney model of 
hypertension (partial occlusion of one renal artery in 
the absence of the contralateral kidney) the situation 
is more clear. Although salt and water is retained in 
the period immediately after induction of this type of 
hypertension (Bianchi, Tenconi and Lucca 1970), this is 
neither a prerequisite for the development of, nor 
essential for the maintenance of the hypertension (Fray, 
Johnson and Barger 1977). 
Previous studies of 1 clip - 2 kidney hypertensive 
dogs suggested that increased PGE production by the 
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untouched kidney several days after the partial 
occlusion of the contralateral renal artery mediated the 
excretion of salt and water that had been retained over 
the first four days (Dighe, Smith, Ungar and Whelpdale 
1978). One of the studies in this thesis aimed to 
further test this hypothesis and at the same time 
provide further information on the role of retained 
sodium and water in mediating transition to established 
hypertension. 
b. MECHANISMS OF PROSTANOID SYNTHESIS 
4.1 Phospholipase 
Most of the prostanoids that are at present thought 
to have important roles in regulation of vascular tone 
and renal function are derived from arachidonic acid 
(C2O:4). Substantial amounts of arachidonic acid in the 
body are esterified to either triglycerides or 
cholesterol esters, particularly for example in the 
renal medulla (Nissen and Bojesen 1969; Cornai, Farber 
and Paulsrud, 1975) but in most tissues the major pool 
of arachidonic acid is in phospholipids (Morgan, Tinker 
and Hananhan 1963; Miller, Kaiser, Baver, Scheiber and 
Hohenegger 1976). Synthesis of prostanoids requires 
initial release of the fatty acid from the phospholipid 
(Lands and Samuelson 1968). Phospholipase A2, the 
enzyme most commonly responsible for this process 
(Flower and Blackwell, 1976) is highly specific, both 
with regard to the position on the phospholipid of the 
fatty acid hydrolyzed (2 position only) (Isakson, Raz 
and Needleman, 1976) and the length of its carbon chain. 
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The metabolic pool of arachidonate available for 
prostanoid synthesis also does not appear to be a single 
entity; changes in fatty acid availability, for example 
by manipulation of dietary intake (Vergroesen, Dedecker, 
Tenhoor and Hornstra 1980) rapidly affect prostanoid 
synthesis, whilst at the same time causing little change 
in the fatty acid composition of membrane phospholipids. 
There are a large number of factors that potentially 
exert control on phospholipase A activity, including 
vasoactive peptide hormones such as bradykinin and 
angiotensin II (Limas and Limas 1979). Whilst the 
availability of free arachidonic acid is certainly a 
major determinant of the rates of prostanoid synthesis, 
the rate of re- acylaton of arachidnoic acid into 
phospholipids, by limiting the amount of free 
arachidonate available, may also be important. 
4.2 Fatty acid oxygenation 
Arachidonic acid is further metabolised to a large 
range of prostanoid products after incorporation of 
molecular oxygen by one of at least three different 
mechanisms (oxygenase reactions). The monoxygenase 
(e.g. lipoxygenase) and dioxygenase (e.g. cyclo- 
oxygenase) reactions are considered by the far most 
important, but a variety of hydroxylated derivatives of 
arachidonic acid can also be synthesised by a mixed 
function oxidase system. Examples of some of the 
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Fig 1. Oxygenation reactions for metabolism for 
arachidonic acid 1 = Cyclo- oxygenase; 2 = 
12- lipoxygenase; 3 = 5 lipoxygenase; 4 = 
Cytochrome P45O mixed function oxidase. 
HPETE = hydroperoxy eicosatetraenoic acid; 




The products of the arachidonic acid cyclo -oxygenase 
reaction have been extensively documented. 
Incorporation of two atoms of molecular oxygen leads to 
'formation of an unstable endoperoxide intermediate which 
is further metabolised to a variety of products. Until 
1976, PGE2, PGF2 and PGD2 were regarded as the 
prostaglandins of most biological significance, but the 
discovery of thromboxane A2 and PGI2 has modified this 
view. Indeed on the basis of biological activity there 
are reasonable grounds to implicate all of these 
metabolites as potential modulators of blood pressure, 
and /or renal function. 
Whilst arachidonate is the major substrate for cyclo- 
oxygenase, other fatty acids such as dihomo ó linolenic 
acid (20:3) and eicosapentaenoic acid (C20:5) are also 
tightly bound to the enzyme although less rapidly 
metabolised to 1 and 3 series prostanoids respectively 
(Needleman, Raz, Minkes, Ferrendelli and Sprecher 1979). 
Phospholipase also releases C20:3 and C20:5 from 
phospholipids. The relative quantities of these 
different fatty acids released in response to a given 
stimulus and therefore competing with arachidonic acid 
for binding to the cyclo -oxygenase enzyme, may serve as 
an important factor determining the relative amounts of 
products formed (Siess, Roth, Scherer, Kurzman, Bohlig 
and Weber 1980). 
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4.2.2. Lipoxygenase 
A single atom of molecular oxygen is inserted into 
the arachidonate molecule by a lipoxygenase system 
(Borgeat, Hamberg and Samuelsson 1976). This occurs 
across CIS double bonds leading to formation of 
chemically unstable epoxide intermediates across the C5- 
6, C11 -12, and C14 -15 double bonds. These epoxides are 
further metabolised, predominantly to the 5 series 
leukotrienes (Murphy, Hammarstrom and Samuelsson 1979), 
12 and 15 hydroxyeicosatetraenoic acids and 15 series 
leukotrienes (Maas, Brash and Oates 1982). 
4.2.3 Mixed function oxidase 
Incorporation of molecular oxygen via a cytrochrome 
P450 dependent mixed function oxidase system also leads 
to formation of a range of unstable epoxide 
intermediates which are further metabolised to a variety 
of hydroxy fatty acids (Oliw, Lawson, Brash and Oates 
1981; Capdevila, Marnett, Chacos, Prough and Estabrook 
1982). 
The biological significance of the lipoxygenase and 
mixed function oxidase products remains uncertain. 
Their mere existence serves to confuse the picture 
since, although under normal circumstances they may have 
little function, they may become important when the 
metabolic pathways are perturbed. For example whilst 
endoperoxides are unstable, they have significant 
biological activity (Feigen, Chapnick, Fleming and 
Kadowitz 1978). Inhibition of their metabolism to, for 
example, thromboxane A2, may well lead to their 
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accumulation and to occupation of any available 
thromboxane receptors (Jones and Wilson 1980). 
Likewise inhibition of cyclo- oxygenase by non - 
steroidal anti -inflammatory drugs, may cause 
accummulation of arachidonic acid, and so increase its 
metabolism by adjacent metabolic pathways such as the 
lipoxygenase or cytochrome P450 systems. These 
possibilities must always be kept in mind when assessing 
the evidence for the importance of these compounds in 
biological systems, where selective inhibitors are the 
only investigation technique utilised. 
Only a limited number of these fatty acid oxygenation 
products are likely to have a significant role in the 
control of blood pressure and renal function. This 
thesis particuarly concentrates on the role of PGE2 and 
PGI2. The importance attached to the function of these 
two prostanoids is based on the description of their 
synthesis by tissues and organs that are most involved 
in the control of renal function and blood pressure. 
5. LOCALISATION OF SYNTHESIS OF PGE2 AND PGI2 IN KIDNEY 
AND VASCULATURE 
PGE2 and PGI2 are both synthesised by vascular 
endothelium (Terragno, Crowshaw, Terragno and McGiff 
1975; Moncada, Higgs and Vane 1977) and isolated 
endothelial cells in culture (Gimbrone and Alexander 
1975; Remuzzi, Mecca, Livio, De Gaetano, Bonati, Pearson 
and Gordon 1980; Whorton, Young, Data, Barchowsky and 
Kent 1982). The distribution of the sites of synthesis 
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of PGE2 and PGI2 within the kidney is complex. The 
renal medulla has a massive capacity to synthesise PGE2 
(Daniels, Hinman, Leach and Muirhead 1967; Larsson and 
Anggard 1973; Frolich, Sweetman, Carr and Oates 1975) 
which is primarily localised in the interstitial cells 
(Muirhead, Germain, Leach Pitcock, Stephenson, Brooks, 
Brosius, Daniels and Kinman 1971; Zusman and Keiser 
1977). Many factors modulate interstitial cell 
synthesis of PGE2 including angiotensin II, bradykinin, 
vasopressin and potassium concentration and osmolarity 
of the surrounding fluid (Zusman and Keiser 1977). 
Indeed the concept of single hormones or factors 
stimulating PGE synthesis is unduly simple. For 
example, aldosterone, although not itself stimulating 
prostaglandin synthesis, alters the stimulation of PGE2 
synthesis by vasopressin, probably by stimulatng 
phospholipase A2 synthesis, thus giving rise to the 
potential for extremely complex multifactorial control 
systems (Zusman and Keiser 1977). The renal cortex also 
synthesisessmall amounts of PGE2 (Frolich, Sweetman, 
Carr and Oates 1975) which may be important functionally 
(see later). Initial reports suggested that PGI2 in 
contrast to PGE2 was primarily synthesised in the renal 
cortex (Remuzzi, Cavenaghi, Mecca, Donati and De Gaetano 
1978; Whorton, Smigel, Oates and Frolich 1978) with 
comparatively little being formed in the renal medulla 
(Whorton, Smigel, Oates and Frolich 1978). More recent 
studies however suggest that PGI2 is also synthesised in 
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significant quantities by renal medullary tissue 
(Okahara, Imanishi and Yamamoto 1983). 
Most investigators agree that prostanoids are likely 
to exert their physiological effects at or near their 
site of synthesis. Studies of prostanoid synthesis in 
whole tissue homogenates of complex organs such as the 
kidney therefore provide limited information. 
Determination of specific cellular sites of 
prostaglandin synthesis within the kidney is difficult, 
particularly because of changes in prostanoid synthesis 
that occur during the tissue separation and 
fractionation procedures. Isolated glomeruli studied in 
this fashion have been shown to synthesise a range of 
arachidonate -derivedproducts particularly PGE2 but also 
PGI2 (Folkert and Schlondorff 1979; Hassid, 
Konieczkowski and Dunn 1979; Sraer, Sraer, Chansel, 
Russo -Marie, Koutnetzova and Ardaillou 1979), some 
thromboxane A2 (Hassid and Dunn 1979; Petrulis, Aikawa 
and Dunn 1981) and to a lesser extent ill- defined 
lipoxygenase products (Lianos and Dunn 1983; Petrulis, 
Aikawa and Dunn 1981). Isolated segments of renal 
vasculature have also been shown to synthesise 
prostaglandins (Terragno, Terragno and McGiff 1978). An 
alternative approach has been to culture cells derived 
from important structures in the renal cortex and 
medulla. Cell culture studies of renal medullary cells 
have already been described but more recent studies have 
also been undertaken using cell lines derived from renal 
cortical tissues. Mesangial cells derived from 
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glomeruli appear primarily to synthesise PGE2, whilst 
glomerular epithelial cells synthesise PGI2 (Kreisberg, 
Karnovsky and Levine 1982). This observation may be of 
considerable functional importance. Mesangial cells are 
contractile and by this means probably alter the surface 
area of the glomerulus available for filtration, thereby 
altering glomerular hydraulic conductivity. Recent 
observations suggest that angiotensin II stimulates PGE2 
release from these mesangial cells (Sharschmidt and Dunn 
1983) which may then modulate the effects of angiotensin 
II on mesangial cell tone. Juxtaglomerular cells which 
synthesise renin have also been grown in cell culture 
(Rightsel, Okamura, Inagami, Pitcock, Takii, Brooks, 
Brown and Muirhead 1982). Both these cells and 
mesangial cells are similar to smooth muscle derived 
cells, and like mesangial cells, the juxtaglomerular 
cells also preferentially appear to synthesise PGE2, in 
addition to much smaller amounts of PGI2 (Watson, 
Inagami and Branch unpublished observations). 
An alternative method of identifying sites of 
prostaglandin synthesis is by using histochemical 
techniques to localise prostaglandin endoperoxide 
synthetase, since prostaglandins are not themselves 
stored in cells. This evidence suggests that there is 
likely to be active synthesis of prostaglandins in the 
collecting ducts of the renal medulla (Janszen and 
Nugteren 1971; Bohman 1977; Smith and Wilkin 1977) and 
in the vascular tissue and to a lesser extent in the 
glomeruli of the renal cortex (Smith and Bell 1978). 
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6. PROSTANOID METABOLISM 
Investigation of the metabolism of prostanoids has 
relied heavily on the mass spectrometric analysis of 
urinary metabolites. The typical approach employed is 
to inject intravenously a mixture of tritiated and 
protonated compound, and make collections of urine 
subsequently voided. Radioactive peaks are separated by 
high performance liquid chromatography and the identity 
of each peak determined by measuring its full mass 
spectrum (Brash, Jackson, Saggesse, Lawson and 
Fitzgerald 1983). Identity of the metabolites then 
permits deductions as to the major routes of metabolism. 
Most prostanoids are metabolised by similar pathways. 
The most important enzymes are prostaglandin 15 - 
hydroxy dehydrogenase and prostaglandin 13 -14 reductase. 
Both lung and kidney contain large amounts of these 
enzymes (Anggard, Larsson and Samuelsson 1971), thus 
PGE2 neither acts as a circulating hormone, nor appears 
in the urine unchanged after an intravenous injection 
(Hamberg and Samuelsson, 1971). As with other fatty 
acids, prostanoids are also susceptible to beta 
oxidation (Hamberg and Samuelson 1972), occurring 
primarily in the liver and kidneys. Further metabolism 
may also occur by both alpha and Omega oxidation 
(Roberts, Sweetman and Oates 1981). The metabolism of 
PGI2 is a little more complex than PGE2. PGI2 itself is 
an unstable compound that spontaneously hydrolyses to 6 
keto PGF1a in aqueous solution (Cho and Allan 1978). 
Whilst both PGI2 and 6 keto PGF1a are substrates for the 
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PG 15 hydroxy dehydrogenase, PGI2 in particular has poor 
affinity for the receptor governing uptake into the lung 
alveolar cells, where most of the enzyme is situated 
(McGuire and Sun 1978). Much of the further metabolism 
of these two compounds therefore occurs in liver and 
kidney, which, as with PGE2, includes in addition to 15 
hydroxy dehydrogenation, alpha, beta and omega oxidation 
(Rosenkranz, Fischer, Weimer and Frolich 1980; Brash, 
Jackson, Saggesse, Lawson and Fitzgerald 1983). Fig 2 
illustrates some of the metabolites of PGI2 most 
prevalent in the urine. 
Metabolism of PGE2 and PGI2 also occurs at the 9 
position on the carbon chain. Prostaglandin 9 
ketoreductase, an NADH dependent enzyme present in both 
liver and kidney, promotes the conversion of PGE2 to 
PGF2a (Leslie and Levine 1973; Lee and Levine 1974; 
Mooreand Hoult 1978). In rabbits activity of this 
enzyme system in the kidney has been related to the 
state of sodium balance (Weber, Larsson and Scherer 
1977). Shunting of PGE2 metabolism through this pathway 
may provide a further means of controlling the local 
concentration of PGE2. 6 keto PGF1a may be metabolised 
by a similar NADPH dependent enzyme, 9 hydroxy 
dehydrogenase to 6 keto PGE1 (Wong, McGiff, Cagan, Malik 
and Sun 1979). This compound has potent activity as 
both a vasodilator and renin secretagogue (Jackson, 
Herzer, Zimmermann, Branch, Oates and Gerkins 1981) and 
this reaction could therefore be of considerable 
significance. However, although there is potential for 
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6 keto PGE 1 synthesis, it remains to be proved whether 
biologically significant quantities of this compound are 
acutally synthesised in vivo (Jackson and Goodman 1981). 
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METABOLISM OF PROSTAGLANDIN 12 
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Fig 2. Metabolic path for metabolism of PGI2. Enzymes 
implicated are 15 hydroxy dehydrogenase, 
13, 14 reductase, Beta and Omega oxidation. 
The hemiketal form of dinor 6 keto PGF 1 , is in 
equilibrium with the open form. Formation 
of the complete lactone is promoted under 
acid conditions. 
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7. RENAL EFFECTS OF PGE2 AND PGI2 
The simplest approach to assessing the effect of PGE2 
and PGI2 on renal function is by infusing the compounds 
directly into the renal artery of anaesthetised animals 
and observing the changes in renal haemodynamics and 
excretory function. Both PGE2 and PGI2 are potent renal 
vasodilators (Jackson, Heideman, Branch and Gerkins 
1982), increments in renal arterial plasma PGE2 
concentration of as low as 25 pg /ml causing significant 
increases in renal blood flow (Jones, Watson and Ungar 
1981). Infusion of low doses of both compounds also 
promotes natriuresis and diuresis (Martinez- Maldonado, 
Tsaparas, Eknoyan and Suki 1972; Bolger, Eisner, Ramwell 
and Slotkoff 1978). Infusion of PGI2 into the kidney 
significantly increases renin release (Bolger, Eisner, 
Ramwell and Slotkoff 1978; Gerber, Keller and Nies 
1979). Most supporting evidence implicating 
prostaglandins in the control of renin release in vivo 
is based on studies using prostaglandin synthetase 
inhibitors (Frolich, Hollifield, Dormois, Frolich, 
Seyberth, Michelakis and Oates 1976; Speckart, Zia, 
Zipser and Horton 1977). Such studies have implicated 
prostaglandins as mediators of renin release as a result 
of baroreceptor and macula densa stimulation (Data, 
Gerber, Crump, Frolich, Hollifield and Nies 1978; 
Blackshear, Spielman, Knox and Romero 1979; Gerber, Nies 
and Olsen 1981). Release as a result of sympathetic 
nervous activity is more likely to be a direct effect 
that does not involve prostaglandins (Berl, Henrich, 
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Erikson and Schrier 1979; Vandongen, Tunney, Mahoney 
and Barden 1981). An important specific role for PGI2 
in this process is further supported by its demonstrated 
ability to release renin from incubated slices of renal 
cortex, and also to enhance release from beta blocked, 
indomethacin treated, non -filtering kidneys (Whorton, 
Misono, Hollifield, Frolich, Inagami and Oates 1977; 
Seymour 1979). 
As already indicated the major action of 
prostaglandins is likely to depend on their site of 
synthesis, since they are unlikely to function as 
circulating hormones. Infusion of prostaglandins into 
the whole kidney therefore provides only limited 
information on their renal actions. The use of 
prostaglandin synthesis inhibitors provides an 
alternative method of investigation. 
In conscious animals inhibition of prostaglandin 
synthesis has comparatively minor effects on renal 
function - inducing no real change in renal 
haemodynamics and if anything a mild natriuresis (Swain, 
Heyndricky, Boettcher and Vatner 1975; Kirschenbaum and 
Stein 1976). In anaesthetised traumatised animals the 
situation is rather different with several studies 
documenting a reduction in renal blood flow, and 
diminuition of sodium and water excretion after 
inhibition of prostaglandin synthesis (Aiken and Vane 
1973; Terragno, Terragno and McGiff 1977; Beilin and 
Bhattacharya 1977; Henrich, Anderson, Berns, McDonald, 
Paulsen, Berl and Schrier 1978). Indeed a period of 
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sodium restriction is sufficient to sensitise the renal 
vasculature to the effects of prostaglandin inhibition 
(Blasingham and Nasjletti 1980). The mechanism of 
stimulation of prostaglandin synthesis under these 
stressful conditions is unclear, but is probably a 
response to associated neuro- humeral events. It is 
known that the renal vasocontrictors angiotensin II and 
noradrenaline, both of which are released during sodium 
restriction (Oliver, Pinto, Sciacca and Cannon 1980) 
stimulate release of PGE2 from the kidney (McGiff, 
Crowshaw, Terragno and Lonigro 1970; McGiff, Crowshaw, 
Terragno, Malik and Lonigro 1972; Rowe and Nasjletti 
1983). The renal vasoconstrictor properties of these 
compounds are enhanced by inhibition of prostaglandin 
synthesis, implying a role for prostaglandins as 
modulators of vascular tone, at least under these 
conditions, in the kidney (Aiken and Vane 1973). 
Furthermore renal nerve stimulation has been clearly 
documented to stimulate renal prostaglandin synthesis, 
particularly PGE2 (Davis and Horton 1972) and the 
effects of renal nerve stimulation are also enhanced by 
inhibition of prostaglandin synthesis (Malik and McGiff 
1975; Henrich, Anderson, Bern, McDonald, Paulsen, Berl 
and Schrier 1978: Susie and Malik 1981). 
All of these findings can best be summarised by 
concluding that under a variety of stressful conditions, 
particularly when the kidney is influenced by 
vasoconstrictor activity, prostaglandins become 
important in maintaining renal blood flow. Having 
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generalised on this point it is still by no means clear 
which particular prostaglandins are most important in 
this respect; this question is addressed in some 
detail in some of the studies to be described. 
Involvement of prostaglandins in control of sodium 
balance is still more controversial. PGE2 and PGI2 
cause natriuresis when infused into the kidney, but 
renal blood flow increases at the same time. It is 
therefore difficult to be certain whether the 
natriuresis is the result of renal vasodilation or 
direct inhibition of tubular sodium transport. 
Micropuncture studies indicate that the latter is a 
distinct possibility (Stokes and Kokko 1977; Stokes 
1979). However, it has been reported (Weber, Larsson 
and Scherer 1977) that a high sodium intake in rabbits 
stimulates conversion of PGE2 to PGF2a via a 
prostaglandin 9 ketoreductase. The resulting reduction 
in PGE2 during sodium loading argues against a direct 
role for PGE2 in promoting sodium excretion. Perhaps 
the decrease in PGE2 levels represents a means by which 
renal renin release is supressed in response to a high 
sodium intake, in view of the known ability of PGE2 to 
stimulate renin release. Other studies in rabbits, dogs 
and man have demonstrated that a low sodium intake 
increases renal synthesis of PGE2, as measured by 
synthesis in incubated sections of kidney (Stahl, 
Attallah, Bloch and Lee 1979) and excretion in both 
urine (Rathaus,Podjarny, Weiss, Ravid, Bauminger and 
Bernheim 1981) and renal venous blood (Oliver, Pinto, 
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Sciacca and Cannon 1980). Whilst this may reflect a 
direct effect of the changes in extracellular fluid 
volume, it is more likely to be due to increased 
adrenergic nervous stimulation and /or renin angiotensin 
activity, supporting the possibility that vasodilator 
prostaglandins modulate the pressor effects of such 
systems. Whilst this is an attractive hypothesis, there 
is also evidence to suggest that pressor activity of 
these systems may be influenced by other factors. For 
example the increase in endogenous concentration of 
angiotensin II during sodium depletion maybe associated 
with increased receptor occupancy (Thurston and Laragh 
1975) and alteration of receptor sensitivity (Strewler, 
Hinrichs, Guido and Hollenberg 1972) and numbers 
(Aguilera and Catt 1981), all factors which might 
decrease the apparent pressor activity of angiotensin 
II. Any role under physiological conditions for 
prostaglandins in this process remains unproven. 
Although it is well established that infusion of PGE2 
and PGI2 into the renal artery induces natriuresis, 
their role as endogenous intra -renal natriuretic 
substance is less clear. Previous studies on human 
subjects have suggested that the increased rate of 
excretion of sodium and water by the kidney which 
follows expansion of the volume of extracellular fluid 
is associated with increased production of renal 
prostaglandins (Papanicoloau, Safar, Hornych, 
Fontaliran, Weiss, Bariety and Milliez 1975; Epstein, 
Lifschitz, Hoffman and Stein 1979). In keeping with 
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these observations, most workers have found that in 
human subjects inhibitors of prostaglandin synthetase 
cause sodium retention (Donker, Arisz, Brentyens, Van 
Der Hem and Hollemans 1976; Berg 1977). By contrast, 
pre- treatment of normal human subjects with indomethacin 
has been shown to enhance the rate of sodium excretion 
after an intravenous infusion of sodium chloride 
solution, suggesting that under certain conditions 
prostaglandins may have anti -natriuretic effects 
(Mountokalakis, Karambasis, Mayopoulou- Symvoulidou and 
Merikas 1978), and this concept receives some support 
from the studies of Kirschenbaum and Stein (1976), who 
observed a natriuretic effect of meclofenamate in 
conscious dogs undergoing water diuresis. Such 
discrepant results are not easy to explain and have been 
further explored in this thesis. 
PGE2 in particular also appears to have a separate 
effect on renal function by modulatng the anti -diuretic 
actions of vasopressin on the collecting ducts. Initial 
studies indicated that PGE1 opposed the action of 
vasopressin on the isolated toad bladder (Orloff, 
Handler and Bergstrom 1965) and collecting duct 
preparations (Grantham and Orloff 1968). In water 
diuresing whole animals it was then shown that 
inhibition of prostaglandin synthesis enhanced the anti- 
diuretic effect of vasopressin (Lum, Aisenbrey, Dunn, 
Berl, Schrier and McDonald 1977). Subsequent studies in 
both the Brattelboro rats (Walker, Whorton, Smigel, 
France and Frolich 1978) and in patients with diabetes 
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insipidus (Fichman, Zia and Zipser 1980) have provided 
supporting evidence for this possible role of 
prostaglandins. 
The apparently contrasting actions of prostaglandins 
under different conditions emphasise that their actions 
on the kidney are likely to depend on the exact site of 
synthesis. For example increased synthesis of 
prostaglandins in the mesangial cells of the glomerulus, 
the afferent arterioles or collecting duct cells must 
certainly have very different effects on renal function. 
8. PGE2, PGI2 AND SYSTEMIC VASCULATURE 
Initial studies with prostaglandins raised the 
possibility, first with PGE2, then with PGA2 and 
finally with PGI2 that they acted as circulating 
vasodepressor hormones. It subsequently became clear 
approximately 70% of PGE1 in venous blood was 
metabolised on single passage through the lungs (Golub, 
Zia, Matsuno and Horton 1975) and that PGA2 in plasma 
was an artifact as a result both of its conversion from 
PGE2 during extraction and insufficiently specific 
radioimmunoassay (Frolich Sweetman, Carr, Hollifield and 
Oates 1975). PGI2 escapes metabolism on the passage 
through the lungs (Dusting, Moncada and Vane 1978) and, 
based on the apparent plasma concentration of its stable 
hydrolysis product, 6 keto PGF1a, was thought to 
circulate in significant concentrations and thus 
possibly act as a circulating hypotensive agent (Hensby, 
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Fitzgerald, Friedman, Lewis and Dollery 1979). 
Subsequent improvements in methodology have now clearly 
established that the plasma concentration of 6 keto 
PGF la is extremely low (Christ -Hazelhof and Nugteren 
1981; Blair, Barrow, Waddell, Lewis and Dollery 1982; 
Siess and Dray 1982), and certainly the concentration of 
PGI2 in the systemic circulation is well below that 
required for a hypotensive effect. 
PGI2 and PGE2 may however exert vasodilator actions 
at or near their site of synthesis. Both compounds are 
synthesised by arteries (Blumberg, Denny, Marshal and 
Needleman 1977; Pace -Asciak, Carrara, Rangaraj and 
Nicolaou 1978) and veins (Hamilton, Rosza and Hutton 
1981). Increased synthesis by arterioles or even venous 
capacitance vessels might well produce sufficient local 
vasodilation to lower blood pressure. In support of 
this hypothesis is some evidence that vasculature from 
spontaneously hypertensive rats has an increased 
capacity to synthesise PGI2 compared with normotensive 
controls (Pace -Asciak, Carrara, Rangaraj and Nicolaou 
1978). 
It is particularly attractive to spectulate that 
vasodilator prostaglandins may be released from the 
systemic vasculature in response to infusion of 
vasoconstrictor compounds such as angiotensin II. In a 
number of in vitro preparations of isolated vascular 
strips, or perfused vascular beds, angiotensin II has 
been reported to release both PGE2 and PGI2 (McGiff, 
Crowshaw, Terragno and Lonigro 1970; Aiken and Vane 
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1973; Shebuski and Aiken 1980; Dusting, Mullins and 
Doyle 1980). On the other hand angiotensin II failed to 
stimulate PGI2 release from vascular endothelial cells 
in culture (Whorton, Young, Data, Barchowsky and Kent 
1982). In all instances however the doses of 
angiotensin II used were well in excess of those likely 
to occur in vivo. If prostaglandins significantly 
modulate the pressor activity of angiotensin II in man 
it might be expected that the pressor response to 
infused angiotensin II would be increased in the 
presence of prostaglandin synthetase inhibitors. 
Several studies in man support this hypothesis (Negus, 
Tannen and Dunn 1976; Vierhapper, Waldhausl and Nowotny 
1981) but the evidence is unconvincing. Renal release 
of renin is inhibited by inhibition of prostaglandin 
synthesis (see previously) and the circulating 
concentration of angiotensin II falls. The change in 
concentration of endogenous angiotensin II alters the 
basis on which the dose response curve is constructed, 
such that the pressor response to infusion of 
angiotensin II is apparently increased, and the 
spurious assumption made that this a consequence of the 
loss of some vasodilator activity. Part of the present 
thesis further addresses this particular question. 
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GENERAL METHODS 
1. PREPARATION OF ANIMAL MODEL 
1.1 Introduction 
The protocol employed for the initial studies 
demanded that the animals remain healthy with patent 
arterial and venous catheters for at least 25 days. 
Despite repeated attempts using numerous different 
methods of inserting catheters into arteries this proved 
possible on only rare occasions (2 out of 25 animals). 
The procedures described below were therefore employed 
(formation of carotid arterial loops) with a subsequent 
dramatic improvement in the success rate achieved. 
Integral to this success was the employment of 
inhalation anaesthesia during the surgical procedures 
and a consistent post- operative antibiotic policy. In 
the studies where catheter patency was required for 
shorter periods (10 days approximately), a satisfactory 
success rate was achieved with chronic indwelling 
catheters. 
1.2 Animals 
Fox hound bitches were used in studies in 2.1 and 2.3 
(weight 16.8 -26.2 kgs) and mongrol bitches in study 2.2 
(weight 17- 24kgs). 
1.3 SurLical Procedures 
1.3.1 Anaesthesia 
After pre- medication with chlorpromazine (50 mgs iv) 
anaesthesia was induced by intravenous thiopentone, an 
endotracheal tube was inserted and a satisfactory depth 
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of anaesthesia subsequently maintained by administration 
of a mixture of oxygen /nitrous oxide /halothane. 
1.3.2. Formation of carotid arterial loop 
The common carotid artery was exposed by a ventral 
mid line incision (15cros long) in the neck and mobilised 
for approximately 12 ems distal to the carotid 
bifurcation. The superior thyroid artery was tied and 
cut. A second slightly shorter incision through the 
skin in the neck was made approximately 7 ems lateral to 
the first. The carotid artery was then drawn into the 
flap of skin formed and the edges opposed and fixed with 
interrupted nylon sutures, so as to place the artery in 
a tunnel of skin. The lateral edges of each incision 
were then drawn together underneath the loop and again 
fixed with interrupted nylon sutures. It was thus 
possible to place at least two fingers between the 
tunnel of skin containing the artery and the skin of the 
rest of the neck. After the operation the neck was 
protected by a light bandage. Twenty -four hours later 
this was changed to a plaster of paris collar around the 
neck to protect the loop from trauma. This was changed 
weekly for three weeks, the sutures being removed after 
two weeks. Healing was complete within one month, the 
plaster was removed and no further protection was 
required thereafter. 
1.3.3 Positioning of renal artery clamp and venous 
catheters 
A laparotomy was performed via a right paramedian 
incision and the right renal artery exposed through the 
33 
posterior peritoneum. A metal externally adjustable 
screw clamp was introduced through a stab wound in the 
subcostal angle and placed on the right renal artery. 
The clamps used were the same as those described 
previously (Dighe, Smith, Ungar and Whelpdale 1978) and 
were held in position around the artery by a metal clip. 
The silastic tube leading to the clamp was buried 
subcutaneously. 
Two silastic catheters (Esco Ltd 1.0 mm internal 
diameter, 2.0 mm external diameter, 70 cm long) were 
introduced at the back of the neck, and with the 
assistance of a metal rod led down the back into the 
abdomen. One catheter was inserted into the left renal 
vein via the left ovarian vein and the other into the 
inferior vena cava, usually via the right ovarian vein. 
Catheters were terminated by metal luer fittings, one 
way metal taps and metal obturators. They were flushed 
on at least every third day with sodium chloride 
solution (150 mmols /l) after removal of the dead space, 
and filled with heparinised saline (1000 iu /ml). 
When arterial catheters were used they were also 
introduced at the back of the neck and lead down to the 
groin. They were then inserted into the femoral artery 
via a small incision. This was closed with thin nylon 
sutures, and the catheter was also fixed to the external 
surface of the vessel by thin nylon sutures. 
Post -operative analgesia was maintained with intra- 
muscular cyclimorph for 36 hours. Sutures were removed 
after 10 days. 
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1.3.4 Placement of flow probes on a renal artery. 
With the animals anaesthetised in the usual fashion 
the left renal artery was exposed by a flank incision. 
An electromagnetic flow probe (Statham 3 or 4 mm 
diameter) was clipped around the vessel and the 
electrical connecting cable was exteriorised via a stab 
incision in the flank. The leads were protected by, and 
carefully sutured to a close fitting nylon jacket which 
the animals wore at all times after the procedure. 
1.3.5 Production of hypertension 
Hypertension was induced by partial occlusion of one 
renal artery by the screw clamp previously positioned in 
the animal. On the day of clamping a control blood 
pressure was first measured and the animals were then 
lightly anaesthetised with thiopentone. The tube from 
the clamp was retrieved through a smallflank incision 
and the screw driver inserted. The screw was turned to 
complete occlusion and then backed off by one and half 
turns (approx 0.8 mm). The blood pressure was monitored 
during the clamping procedure and in most cases there 
was an immediate increase in mean pressure of 10 -15 
mmHg, which returned to control values over the ensuing 
5 minutes. 
1.4 Diets 
The animals were given two separate diets depending 
on the period in the study (study 2.1 only). During the 
high sodium period they received a diet containing an 
estimated 60 mmols of sodium and 40 mmols of potassium 
per day. During the low sodium period the diet 
35 
contained less than 10 mmols of sodium per day and 
potassium capsules (KC1) were given to maintain a daily 
potassium intake of 40 mmols. Duplicate diets were 
analysed for sodium and potassium content and these 
estimates were confirmed. 
1.5 RecordinL of blood pressures heart rate and renal 
blood flow 
The dogs were introduced to the recording room one 
week after the initial operation and trained to sit on a 
table where the blood pressure would subsequently be 
recorded. The arterial loops were cannulated with a 19 
guage butterfly needle (Abbot ltd) with prior local 
anaesthetic (2% W/V lignocaine). The first blood 
pressure recording was obtained three weeks after 
formation of the loop. Further recordings were then 
obtained during the control period after laparotomy and 
placement of clamp and catheters. The pressure was 
obtained from the arterial catheter (Consolidated 
Electro- dynamics L223 or Statham P36 pressure 
transducers) and mean blood pressure was continuously 
recorded during each session for at least one hour, 
while pulsatile pressure, from which heart rate was 
derived was recorded for 5 minutes at 15 minute 
intervals. 
The electrical scale of the pressure recording 
system was calibrated at approximately three monthly 
intervals with a mercury manometer system. Day to day 
calibration of the system was then made with reference 
to this electrical scale. The frequency response of the 
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entire pressure recording system was flat within 5% up 
to 25 Hz. 
In studies in which renal blood flow was measured 
(study 2.2) the animals were kept upright in a harness 
system. The flow probe was connected to a meter 
(Statham) and the system calibrated with reference to an 
electrical zero. The signal for mean renal blood flow 
was then continuously recorded on a Hewlett Packard 
chart recorder. The electrical zero position of the 
meter was confirmed at the end of the study by 
intravenous injection of 2 ugms of angiotensin II, which 
transiently reduce renal blood flow to zero. 
1.6. Urine collection procedures 
Achievement of satisfactory sodium and potassium 
balance was confirmed by collection of urine excreted 
over a 24 hour period. During this time the animals 
remained in their kennels, apart from a short episode of 
supervised excerise. A false base was inserted into the 
kennel so that all urine voided was collected in a 
stainless steel tray. 
In two of the studies (2.2 and 2.3), catheters were 
inserted into the bladder to permit continuous 
collection of urine for periods of up to six hours. 
Catheters were either inserted after induction of light 
anaesthesia with intravenous thiopentone, (study 2.3) or 
the conscious animal was catheterised (study 2.2). The 
urine was allowed to continuously drain into a flask 
during a collection period, and at the end of the period 
complete bladder empyting was ensured by manual 
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palpation and injection of air. 
2. MEASUREMENT OF RENAL PLASMA FLOWz GLOMERULAR 
FILTRATION RATE) SAMPLE COLLECTION AND ANALYTICAL 
METHODS 
2.1 Introduction 
In one of the studies (study 2.2) renal blood flow 
was monitored directly from an indwelling 
electromagnetic flow probe placed around a renal artery. 
In all other studies renal plasma flow was derived 
indirectly from the clearance of p -amino hippurate 
(PAH). Glomerular filtration rate was always measured 
by a clearance technique. 
2.2 Clearance techniques 
For most studies PAH and inulin clearances were 
measured simultaneously. A loading intravenous dose of 
each compound was first given followed by a continuous 
intravenous infusion of a suitable dilution of the 
compounds in dextrose solution (50g /1) so as to maintain 
plasma levels of approximately 3 and 20 mg /100mis of PAH 
and inulin respectively. The loading dose of each 
compound was varied according to body weight, based on 
assumed distribution throughout the extracellular fluid 
volume. 
Urine collected during timed periods was analysed for 
PAH and inulin. Similarly blood samples were always 
collected at the beginning and end of each period and 
analysed in the same way. A mean value was then 
determined from the two plasma results, which was then 
used for calculation of clearances. 
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In study 2.2 glomerular filtration rate was 
calculated from the clearance of 99Tc diethylene 
triaminepentaacetic acid (DTPA). The method is 
very similar to that for inulin, except that radio- 
activity of the samples is determined, rather than 
chemical assay of a compound. 
2.3 Sample collection and techniques of analysis 
2.3.1 Sample collection 
Blood samples were collected into tubes at 1 °C 
containing either lithium heparin, EDTA (for analysis 
of plasma renin activity and aldosterone, study 2) or 
pepstatin and nonapeptide converting enzyme inhibitor 
(angiotensin II ). All samples were kept on ice, 
centrifuged at 2000g for 20 minutes soon after 
collection, and the plasma was separated and stored at - 
20 °C. 
Urine samples were collected at room temperature, 
their volume measured and then separated into aliquots 
which were stored at -20 °C or -70 °C (prostaglandin 
samples). 
2.3.2 Routine laboratory analysis 
Plasma and urine, sodium and potassium were measured 
by flame photometry (Corning 430). A freezing point 
depression method was used for osmolality (Advanced Inst 
Inc), and a standard autoanalyser technique for urea and 
creatinine (Technieon autoanalyser). Inulin was 
measured by a modification of Heyrovsky's technique for 
automatic analysis (Technicon antoanalyser) (Dawborn 
1965). In brief the inulin was hydrolysed to fructose 
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by heating with hydrochloric acid. After removal of 
protein by dialysis the colour was developed by 
incubation with concentrated hydrochloric acid and 3- 
indolylacetic acid and its intensity measured in a 
spectrophotometer recording absorbance at 520 nm. 
PAH was also measured on an autoanalyser system 
(Technicon autoanalyser) (Harvey and Brothers 1962). 
The compound was first removed from urine and plasma by 
dialysis and subsequently diazotised with nitrite. The 
excess nitrite was destroyed by sulphamate and the 
colour produced by developing with N(1- Naphthyl) 
ethylene diamine dihydrochloride was monitored at 550 
nm. 
Radioactivity of DTPA was measured in 1 ml of urine 
and plasma with an automated gamma counter (Packard Inst 
Co). 
2.3.3 Radioimmunoassays 
2.3.3.1 Plasma renin activity, angiotensin II and 
aldosterone. 
The method for measurment of plasma renin activity is 
well described (Haber, Koerner, Page, Kilman and Purnode 
1969) and based on the generation of angiotensin I 
during incubation of the samples at 37 °C. Commercially 
available antibody and radioactive angiotensin I 
(C.I.S.) were used throughout. In the initial studies a 
commercial assay kit was used (C.I.S. Ltd), but later a 
modified system was used (Roulston, Wathen, Sanger and 
Muir 1983) which gave results similar to those with the 
commercial kit, but less susceptible to interference by 
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plasma being kept too warm during sample collection. 
In study 2.2 aldosterone was measured by a commercial 
system (C.I.S. Ltd) that did not require extraction of 
the plasma samples (McKenzie and Clements 1974). In 
other studies aldosterone was first extracted from 
plasma prior to assay. Angiotensin II was measured on 
unextracted plasma samples using the method in routine 
use in the Department of Endocrinology, Vanderbilt 
University (Dr R J Workman). 
2.3.3.2 Prostaglandin E2 (Plasma) 
The method was based on that described by Dray et al 
(Dray, Charbonnel and MacLouf 1975) and was a further 
modification of that developed by Dr K K Dighe in the 
Department of Pharmacology, Edinburgh University. In 
brief, 1 ml of plasma was extracted, after acidification 
to pH 3, with ethyl acetate (x3). The organic fractions 
were pooled, dried and then subjected to silicic acid 
chromatography (Unisil). The fraction containing PGE2 
was dried and the residue resuspended in phosphate 
buffer. The PGE content was quantified by a 
radioimmunoassay system using specific rabbit anti -PGE 
antibody (Institut Pasteur, Paris), and 3HPGE2 (Amersham 
Chemicals). A double antibody method was used to 
separate the antibody bound from free tracer (Dighe, 
Emslie, Henderson, Simon and Rutherford 1975). Since 
recovery of PGE from plasma was less than 100 %, the 
recovery was determined from the mean recovery of 3H 
PGE2 added to a standard plasma, and extracted in 
parallel with the unknown. Mean recovery of PGE2 in 
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these samples was 44 +2 %. The appropriate correction 
factor could then be used when calculating the final 
concentration of PGE in the unknown samples. 
2.3.3.3 Prostaglandin E2 (urine) 
The method is a further modification of that 
described above for plasma. A small quantity of 3H PGE2 
was first added to 5 -10 ml urine to permit subsequent 
calculation of recovery of extracted PGE2. After 
acidification (pH3.0) the urine was passed through a C18 
Sep -Pak (Waters Associates). The column was washed with 
water followed by 20% Ethanol:80% water and the retained 
prostaglandin was then eluted with ethyl acetate. The 
eluate was taken to dryness and the residue resuspended 
in phosphate buffer. The 3H PGE2 content of part of 
this fraction was determined to permit calculation of 
recovery, and aliquots of the remainder were subjected 
to radioimmunoassay by the same system described above. 
Recovery of extracted PGE2 was 82 +5% by this method. 
2.3.4 Mass Spectrometry 
2.3.4.1 Introduction 
Gas chromatography in combination with a mass 
spectrometer (GC -MS) has proved to be a useful technique 
for quantitative analysis of prostaglandins. Before a 
final analysis on such a system most biological samples 
have to be substantially purified by organic extractions 
and chromatography. The size of the sample required for 
extraction is determined by the sensitivity of detection 
of the compound in the mass spectrometer. The most 
widely used method of inducing molecular fragmentation 
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within the mass spectrometer is by electron impact 
ionisation. Whilst this usually provides a large range 
of molecular fragments, any one of which can be 
monitored with the instrument in single ion mode, the 
sensitivity of detection of any one of these ions is 
limited, since each constitutes only a small proportion 
of the total ion current. Ionisation techniques that 
limit molecular fragmentation permit selection of ions 
for monitoring that constitute a much larger proportion 
of the total ion current, with corresponding gains in 
the sensitivity of detection. Chemical ionisation is a 
useful means of inducing such ionisation and has been 
widely used in the analysis of prostaglandins (Suzuki, 
Morita, Kawamura,Murota, Nishizawa, Miyatake, Nagase, 
Ohno and Shimizu 1980). An alternative approach has 
been to use chemical ionisation techniques, but to 
measure the negatively charged ions formed in the ion 
source, negative ion chemical ionisation mass 
spectrometry (NICI) (Dougherty 1981). The great 
sensitivity of this method for measuring certain 
prostaglandins has already been reported (Blair, Barrow, 
Waddell, Lewis and Dollery 1982). The method to be 
described was specifically developed for analysis of a 
urinary metabolite of PGI2, 2,3 dinor 6 keto PGF1a' 
2.3.4.2 Preparation of standard fatty acid derivatives. 
In order to optimise the working conditions of the 
mass spectrometer in NICI mode, electrophilic fatty acid 
derivatives were synthesized. The pentafluorobenzyl 
ester of stearic acid was synthesized by extractive 
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alkylation (Rosenfeld, Ting and Phatak 1981). 100 ul of 
a 25% (W /V) solution of tetrabutyl ammonium in methanol 
was added to 900 ul of 0.1 M solution of sodium 
carbonate. Stearic acid was added (0.5 mg in 1 ml 
dichloromethane) and reacted for 2 hours at 25 °C. 10 ul 
of a solution of pentafluorobenzyl bromide (60 ul in 200 
ul of acetonitrile) was added. After 10 minutes the 
upper aqueous phase was removed. The fatty acid 
pentafluorobenzyl ester remained in the organic phase. 
2.3.4.3 Separation of 2,3 dinor 6 keto PGF1a from urine 
and its derivatisation. 
The procedure was a modification of that described by 
Falardeau et al ( Falardeau, Oates and Brash 1981) and 
relies on separation of 2,3 dinor 6 keto PGF1a from 
other carboxylic acids by utilising its ability to form 
a complete lactone under acid conditions thereby 
manipulating its solubility in polar and non -polar 
organic solvents (Fig 2). 
Urine (5 -10 mis) was spiked with 10 ng of d4 dinor 
6 keto PGF1a' After initial alkalinisation to pH 10 the 
mixture was acidified to pH2 with concentrated 
hydrochloric acid. This was poured onto a 5 or 10 ml 
capacity Clin -Elut column and the prostaglandin was 
eluted with two volumes of dichloromethane into 
sialinized glass tubes. The eluate was extracted 3 
times with 5 or 10 ml of pH 8 borate buffer (0.05 M 
sodium borate) and the aqueous phase was discarded. 
After evaporation of dichloromethane with nitrogen the 
sample was taken up in 50 ul pyridine and mixed with 1 
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ml of borate buffer. After standing 10 mins this was 
extracted twice with 10 ml ethyl acetate and the organic 
phase was discarded. The aqueous phase was acidified to 
pH2 with concentrated hydrochloric acid and extracted 
with 4 ml dichloromethane. The aqueous phase was 
discarded and the dichloromethane was evaporated under 
nitrogen. The residue was then redissolved in 20 ul 
pyridine and the methoxime derivative formed by addition 
of an excess of methoxyamine hydrochloride in the 
presence of triethylamine, followed by incubation for 1 
hour at 60 °C. Pyridine was evaporated with nitrogen and 
the pentafluorbenzyl ester formed by addition of 15 ul 
of pentafluorobenzyl bromide (50 ul in 200 ul 
acetonitrile), 10 ul of diisopropylethylamine (60 ul in 
250 ul acetonitrile) and 20 ul of acetonitrile, followed 
by incubation at 50 °C for 20 minutes. After evaporation 
under nitrogen, the sample was resuspended in 20 ul 
acetonitrile and applied to a thin layer chromatography 
plate (Whatman LK6DF linear K Silica gel, 250 um thick 
with preadsorbent zone), and developed in a solvent 
system of ethyl acetate:methanol (98:2). Dinor 6 keto 
PGF1a had an Rf of approximately 0.15 in this system, 
but its exact position on the plate was determined by 
running a similarly derivatised standard in parallel and 
subsequently staining this part of the plate with a 
colour reagent (calcium sulphate 5 g, sulphuric acid 
(con) 20 ml and water 100 ml). The region of interest 
was scrapped from the plate and after addition of 250 ul 
of water (containing 0.1% acetic acid) the prostaglandin 
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was extracted into a 5 fold excess of ethyl acetate. 
The organic phase was separated, taken to dryness and 
derivatised with N,N- bis- (trimethyl silyl) 
trifluoroacetamide (BSTFA) to form the methoxime 
trimethyl silyl ether derivative. 
2.3.4.4 Gas chromatography - mass sepctrometry system 
A Hewlett Packard HP 5982 mass spectrometer was 
modified for use in the negative ion mode (Dr B J 
Sweetman and Mr W Levine) (Fig 3). The reagent gas used 
was the same as the carrier gas for the gas 
chromatography system (3 foot SP 2100 column) and could 
therefore be led directly into the ion source of the 
mass spectrometer via a jet separator. Estimates of ion 
source pressure were derived from the pressure in the 
manifold. Methane was routinely used as the carrier 
gas, which with a column temperature of 260 °C gave a 
retention time of 4.7 minutes for dinor 6 keto PGF1a 
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Fig 3. Schematic representation of HP5982 mass 
spectrometer modified for negative ion chemical 
ionisation. Chemical ionisation is induced in 
the ion source in a methane atmostphere. 
Repeller, ion focus and draw out plates and the 
entrance lens are all held at a negative charge 
to repel the ions into the quadripole 
analyser. The positively charged x -ray plate 
draws out the ions which are detected on the 
electron multiplier. 
47 
2.3.4.5. Quantitation by GC -MS. 
Derivatised standards containing constant amounts of 
d4 dinor 6 keto PGF1a, and variable quantities of the 
protonated form were prepared by the method above. A 
standard calibration curve could then be constructed by 
measuring peak sizes of d° and d4 compounds (586 and 590 
m/z respectively) in the different samples. Amounts of 
d° dinor 6 keto PGF1a in particular biological samples 
could then be calculated by reference to the standard 
curve. The d° blank obtained using pure d4 standard was 
in the region of 0.5 %. 
2.4 Calculation of results. 
2.4.1 Clearance 
Clearance (C) of all compounds (n) was calculated from 
the following formula 
UnV 
Cn = T 
where Un = concentration (or activity in the case of 
osmoles) in urine 
V = urine flow rate 
Pn = concentration or activity of the compound in 
plasma 
In this thesis n is restricted to inulin, PAH, 
creatinine and osmoles. 
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2.14.2 Expression and analysis of results 
All results have been expressed as mean + standard 
error of the mean. Comparisons between samples have 
been made with students two tailed t test for paired or 
unpaired samples. On occasion non -parametric analysis 
with Wilcoxon sign rank test was used. The null 
hypothesis for differences between the samples was 
rejected when P < 0.05. 
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RESULTS 
1. ANALYTICAL METHODS FOR PROSTAGLANDINS 
1.1 Validation of radioimmunoassay for PGE 
Precision of the analytical system for urinary PGE 
was determined by extracting different volumes of the 
same urine sample and determining the amount of PGE 
present by analysing an appropriate volume of eluate 
from the Sep -Pak. Fig 4 demonstrates that there was 
linearity between the volume of urine extracted and the 
PGE detected over an appropriate working range. 
Addition of known varying amounts of PGE to a fixed 
volume of urine allowed assessment of the acurracy of 
the system. There was again reasonable linearity 
between the amount of PGE added and the amount detected 
by radioimmunoassay (Fig 5). 
Many of the studies involved the assessment of 
effective renal plasma flow by PAH clearance. PAH is an 
organic acid which may only be partially removed from 
urine by the Sep Pak system, its potential for 
interfering with the assay system was therefore 
assessed. Known varying amounts of PAH were added to a 
fixed volume of urine. Samples were extracted and 
analysed in the usual fashion. Although very high 
concentrations of PAH may have interfered with the assay 
(fig 6), this was not a significant factor in the 
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Fig 4. Effect of the volume of urine extracted on the 
amount of PGE detected by radioimmunoassay. 
Broken line indicates expected values if 


















Fig 5. Effect of addition of varying quantities of PGE2 
(pg /ml urine) to a fixed volume of the same urine 
sample on the amount of PGE detected by 
radioimmunoassay. Broken line indicates expected 
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Fig 6. Effect of increasing concentration of PAH (3.5 
mg /ml to 350 mg /ml) on the amount of PGE 
detected in the same sample of urine. Results 
expressed as log10 of concentration of PAH. 
Broken line indicates expected values if PAH 
does not interfere with the assay. 
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1.2 Optimisation of as chromatLraphy mass spectrometrL 
s /stem for dinor 6 keto PGF1a 
1.2.1 Reagent gas and sensitivity of detection. 
Although satisfactory negative ion chemical 
ionisation spectra of fatty acid and prostaglandin 
pentafluorobenzyl ester methoxime trimethylsilyl ether 
derivatives were obtained with both ammonia and argon as 
reagent gasses, the greatest sensitivity was obtained 
with methane. In this reagent gas the pentafluorobenzyl 
ester of prostaglandins tested, and stearate, ionised 
with at least 50% of the total ion current being 
accounted for by the M -pentafluorobenzyl fragment (Fig 
7). This contrasts with the fragmentation pattern when 
the same molecule is ionised by the more usual electron 
impact method (Fig 8). Many more ion fragments are 
produced and the proportion of the total ion current in 
any one fragment is comparatively small. The operating 
conditions of the instrument were then optimised using 
stearate pentafluorobenzyl ester and monitoring M/Z 
(mass /energy) in single ion monitoring mode. Although 
ion source pressure was not monitored directly, this 
was reflected in changes in flight tube manifold 
pressure. An early finding was that this pressure of 
reagent gas critically determined ionisation efficiency 
Increased pressure in the ion source was produced by 
increasing the methane flow through the gas chromatogram 
column. Increasing methane flow through the column 
however, also shortens the retention time of any 
compound on the gas chromatogram. To standardise the 
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effects of changes in ion source pressure the 
temperature of the gas chromatography column was varied 
to maintain a constant compound retention time for any 
particular gas flow. With this system it was possible 
to demonstrate in excess of 100 fold changes in 
sensitivity of detection over a manifold pressure range 
of 2.8 - 14 x 10 -6 torr (Fig 9). Under optimal 
operating conditions it was possible to detect, with a 
signal to noise ratio of better than 3 -1, as little as 
25 fg of stearate and approximately 350 fg of 6 keto 








Negative Ion (CH4) 
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m/z 
Fig 7. Negative ion spectrum of 6 keto PGF1a 
pentaflurobenzyl ester methoxime trimethyl 
silyl ether. Loss of pentaflurobenzyl group 
leaves the molecular fragment (614 m /z) by 
far the most abundant ion. HP 5982 mass 
spectrometer. 
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Fig 8. Electron impact ionisation spectra of 6 keto 
PGF1a pentaflurobenzyl ester methoxime 
trimethyl silyl ether. Relatively abundant 
ions are M -31 (7614) - loss of OCH3 and M -121 
(674) - loss of OCH3 and OTMS. M -PFB is not 
a significant ion. 
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EFFECT OF METHANE PRESSURE (MANIFOLD) 
ON RESPONSE (SAM.) 
RESPONSE 
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Fig 9. Dependency of sensitivity of detection of 6 keto 
PGF1a PFBMOTMS on methane pressure in the ion 
source manifold. Gas chromatography operating 
temperature was manipulated to ensure a 
retention time of approx 2 mins. 
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NEGATIVE ION G.C.- M.S. (S,I,M.) OF 6 KETO PGFQ PFB MO TMS 
I 2 
I 1 Pen Offset 
Fig 10. Maximum sensitivity of çletection of 6 keto 
PGF1a PFBMOTMS. 50 pg d4 derivative applied 
to the column, known d° component 7:1000. 
Hexane blank for base line comparison. 
Retention time at 260 °C. Machine in 
selective ion monitoring mode. 
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1.2.2 Application to urinary and plasma 2,3 dinor 6 
keto PGF1a estimation. 
The sensitivity of detection of the compound was such 
that prostaglandin extracted from 0.5 - 2 mis of urine 
was sufficient to provide an excellent signal in the d° 
channel, the typical concentration in urine being 100- 
200 pg /ml. Precision of the assay was determined by 
extracting different volumes of the same urine sample 
(Fig 1 1 ). Accuracy was determined by extracting fixed 
volumes of the same urine samples, spiked with 
increasing amounts of protonated standard (Fig 12). In 
each case there was linearity between the amount 
detected and the amount extracted. 
Plasma samples were extracted in the same way as 
urine samples. Since the concentration in plasma was 
lower than that in urine the system was operated at high 
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Fig 11. Peak ratio d ° /d14 of dinor 6 keto PGF1 as function of volume of urine extracted. d 
blank equivalent to 5:1000 of d14 standards. 
Broken line indicates expected values if 
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Fig 12. Peak ratio d ° /d4 on addition of varying amounts 
of protonated dinor 6 keto PGF1a to a fixed 
volume of urine (20 ml). 
Broken line indicates expected values if 
detection is linear. 
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2.ANIMAL STUDIES 
Four different studies are described in this section: - 
2.1 Extracellular fluid volume expansion and the 
development of one clip two kidney hypertension. 
2.2 Systemic angiotensin II infusion and PGI2 release. 
2.3 Systemic and renal vascular sensitivity to 
angiotensin II in normotensive and hypertensive dogs. 
2.4 Interstitial cell morphology and the development of 
one clip -two kidney hypertension. 
2.1 Extracellular fluid volume expansion and the 
development of one clip two kidneLr hypertension. 
The potential role of sodium and water retained in 
the early period after partial occlusion of a renal 
artery in the development of established hypertension in 
conscious dogs has been discussed in the introduction. 
To explore further the role the sodium and water that 
accummulates during the two days after the partial 
occlusion of one renal arteryit was removed by 
haemodialysis. Subsequent retention of sodium and water 
was prevented for seven days by feeding a low sodium 
diet. Plasma levels of renin, aldosterone and PGE were 
monitored at intervals and the development of 
hypertension was observed. 
2.1.1 Protocol and Special Methods 
The protocol for the timing of blood pressure 
recordings, induction of hypertension, dialysis and 
dietary restrictions are illustrated in Fig 13. 
Haemodialysis was undertaken on day 3, 48 hours after 
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partial occlusion of a renal artery, with an EX 20 1m 2 
coil (Extracorporeal), paediatric connecting lines 
(Travenol) and a roller pump. The arterial blood supply 
was taken from the carotid artery loop and venous return 
was via a 17 gauge Medicut inserted into a foreleg vein. 
Ultrafiltraton was achieved with a blood flow of 
approximately 120 mis /min and the pressure in the venous 
return circuit was maintained at approximately 200 mmHg. 
The ultrafiltrate from the coil was collected in a 
measuring cylinder. Before dialysis the dogs were 
heparinised with 5000 i.u. injected intravenously and 
at the end of the dialysis anticoagulation was reversed 
with an equivalent quantity of protamine. Each dialysis 
lasted for approximately 2 hours during which time the 
animals remained in the sitting position. The length of 
each dialysis and the rate of fluid removal was 
determined by the quantity of fluid to be removed. 
Fluid gain and loss from day to day and before and after 
dialysis were estimated from changes in body weight. 
The animals were weighed at the same time each day on an 
electronic weighing balance with an electronic 
integrator which gave results that were accurate to 
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Fig 13. Protocol for procedures and recordings. The 
control period started 10 days after 
laparotomy for placing renal artery clamp 
and catheters. Each recording period lasts 
about one hour. 
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2.1.2 Results 
2.1.2.1 Body weight and packed cell volume (PCV) 
The weight of the animals (n =6) increased by a mean 
of 0.49 kg between the clamping of the renal artery on 
day 1 and day 3 (22.40 + 1.3 - 22.89 + 1.4 kg, p<0.01). 
There was also a significant increase in weight between 
days 10 and 13 (21.35 + 1.1 - 22.07 + 1.2 kg p <0.02). 
There were substantial long -term changes in body weight 
particularly during the low sodium period, which were 
almost certainly a result of changes in nitrogen 
balance. The large short term changes in body weight 
described are likely to be due to changes in fluid 
balance, the increase in weight between days 1 and 3 
representing a mean accumulation of 76 mmols of sodium. 
PCV decreased significantly between days 1 and 3 (38.3 + 
1.4 - 33.9 + 1.4 %, p <0.005). 
2.1.2.2 Plasma creatinine and electrolytes 
There was no significant change in plasma 
concentration of sodium (mean control value 146 + 1.6 
mmols /l) or potassium (mean control value 3.9 + 0.2 
mmols/l) throughout the course of the study. There was 
in particular no decrease in plasma sodium concentration 
between days 1 and 3 indicating that the increase in 
weight was due to retention of both salt and water. The 
concentration of sodium in the ultrafiltrate produced 
during dialysis was identical with the plasma sodium 
concentration of the animal on each occasion. There 
was no evidence of deterioration in renal function at 
any stage, with plasma creatinine concentration never 
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increasing above 100 umol /1 in any animal. 
2.1.2.3 Blood pressure and heart rate. 
Mean blood pressure increased by 24 mmHg within 2 
days of partial occlusion of a renal artery (91.8 + 0.9 
- 116.5 + 2.7 mmHg, p <0.001) (Fig 14). Dialysis on day 
3 was not followed by a significant change in blood 
pressure until day 10, indicating that the acute 
accummulation of fluid after partial renal artery 
occlusion was not necessary for the maintenance of 
hypertension. The decrease of 8 mmHg in blood pressure 
during the period of sodium restriction between days 3 
and 10 (p <0.05) was followed by a small but significant 
increase (6 mm Hg) after the restoration of sodium 
intake between days 10 and 17 (p< 0.01). The results of 
blood pressure estimations on day 19 are not shown, 
since one of the animals had dropped out of the series, 
however, the pressure at day 19 in the remaining 
animals was not significantly different from the 
pressure on day 10. 
The heart rate decreased significantly between 1 and 3 
(94.0 + 3.8 - 70.0 + 3.7 beats /min, p < 0.005) but 
progressively increased during the low sodium period to 
95 + 12 beats /min on day 10 (p < 0.05) (Fig 14). 
Institution of a normal sodium intake on day 10 resulted 
in a small decrease in heart rate, which on day 17 was 
not significantly different from the control value. The 
product of heart rate and pulse pressure maybe taken as 
an approximate index of cardiac output. The results 
from this study (Fig 14), suggest that there was an 
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initial fall in cardiac output between days 1 and 3 with 
a subsequent progressive increase between days 3 and 10. 
Between days 10 and 17 there was a return to the values 
which were very similar to those obtained during the 
control period. 
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Fig 14. Product of heartrate and pulse pressure 
(HRxPP), heartrate (HR) and blood pressure 
(BP) before and after the induction of 
hypertension. 
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2.1.2.4 Endocrine Changes 
Partial occlusion of one renal artery resulted in a 
significant increase in arterial plasma renin activity 
(3.4 + 0.3 - 10.5 + 1.5 ng /h /ml, P < 0.005), which 
remained high during the period of low sodium intake. 
There was then a gradual decrease in the concentration, 
although by day 17 it was still significantly higher 
(5.7 + 1.7 ng /nil) than the control level (P < 0.05) (Fig 
15). Plasma renin activity in renal venous plasma from 
the untouched kidney paralleled levels in arterial blood 
during the study, suggesting that almost all of the 
renin was released from the clamped kidney. 
The time course of the change in arterial plasma 
concentration of aldosterone was similar to that of 
renin (Fig 15), although the level of aldosterone 
continued to rise until day 5, whereas plasma renin 
activity reached its maximum on day 3. As with renin, 
the aldosterone level remained significantly elevated at 
day 17 compared with control value (P < 0.05). Despite 
the changes in sodium balance and arterial plasma renin 
activity, there were no significant changes in the 
arterial and renal venous plasma concentration of PGE 
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Fig 15. Plasma aldosterone, plasma renin activity, 
(PRA) and plasma PGE before and after 
induction of hypertension. j---s = Arterial = Renal venous 
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2.1.2.5 Urinary Output 
The results of 24 hour urine volume, sodium and 
potassium excretion and creatìnine clearances are shown 
in Table 1. The results show that the animals were in 
similar sodium balance during both the control period 
and postclamp period, while taking the same high sodium 
diet. During the low sodium diet there was avid sodium 
retention with a mean urinary excretion of only 8.6 
mmols /211 hrs. 
72 
,ér\%'Ypf'.!. ,,rwc.%i*wK 3 
t1Y h : _;.il i+.... Yti..R 
y. -, ~ 8 »14Ai ;`77''', 
.1 . _ :..í.ÿ.v ! . 
... ._v . .. _ _... ... .`.... ..:Y 
TABLE 1. PARAMETERS OF RENAL FUNCTION DURING 24 -H URINE 
COLLECTION PERIODS 
Diet... High Sodium Low Sodium 
Time... Control Postclamp Postclamp 
(n =5) (n =11) (n =6) 
V 
(ml/24 h) 
583+51 628+78 523+53 
UNaV 
(mmol/24 h) 
55+7 48+18 9+3.5 
UkV 
(mmol/24 h) 
44+2 47+4 38+3 
CrC1 
(ml/min) 
44+10 65+16 42+10 
Urine flow rate (V), sodium excretion (U V), potassium excretion 
(UkV) and creatinine clearance (CrC1) derived from urine collections 
during periods of high- and low- sodium intake before (control) and 
after induction of hypertension (postclamp). n= Number of collection 
periods. 
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2.2 Systemic angiotensin II infusion and PGI2 release 
Evidence that the vasodilator prostaglandin PGI2 
modulates the vasoconstrictor activity of angiotensin II 
is mainly derived from studies in vitro and in 
anaesthetised animals. However the extent to which PGI2 
modulates the systemic vasoconstrictor activity of 
angiotensin II in conscious animals has not been 
established. The objective of this study was to 
determine whether infusion of angiotensin II into 
conscious dogs in a dose sufficient to cause a modest 
increase in systemic blood pressure and renal vascular 
resistance also resulted in increased release of PGI2 
into the systemic circulation, as assessed by 
measurement of plasma and urinary levels of its stable 
metabolite dinor 6 keto PGF1a* 
2.2.1 Protocol and Special Methods 
On the day of the study the urinary bladder was 
catheterised without anaesthesia. An initial 
intravenous infusion of 500 ml of dextrose solution (50 
g /1) was given over 30 minutes via a catheter in the 
inferior vena cava, followed by continuous infusion of 
dextrose solution (50 g /1) at 3 ml /min and sodium 
chloride solution (150 mmol /1) at 0.6 ml /min using a 
Harvard infusion pump. After a 60 min control period 
either the sodium chloride infusion was continued 
(vehicle) or a freshly prepared solution containing 
angiotensin II amide (Hypertensin, Ciba) in sodium 
chloride solution was substituted. The concentration of 
angiotensin II solution was adjusted for each dog such 
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that the final rate of infusion was 15 ng /min /kg body 
weight. After a further 180 min sodium chloride 
solution was substituted for the angiotensin II and the 
infusion continued for a further 60 min recovery 
period. 
To permit calculation of glomerular filtration rate 
99Tc DTPA in sodium chloride solution was also 
continuously infused via the same catheter at a rate of 
0.18 ml /min (Harvard pump), after an appropriate loading 
dose. After an initial period of 90 min, 30 min urine 
collections were made throughout the study. Blood 
samples were also collected every 30 min for estimation 
of DTPA activity, while samples for estimation of plasma 
renin activity, angiotensin II, aldosterone, dinor 6 
keto PGF1a and haematocrit were collected every hour. 
Each of the six animals underwent two studies during 
which either angiotensin II or vehicle was infused. 
2.2.2. Results 
2.2.2.1 Renal and systemic haemodynamics 
There were no significant differences in systemic 
blood pressure, glomerular filtration rate and renal 
blood flow between the two groups during the control 
period. On starting infusion of angiotensin II there 
was a prompt increase in systemic blood pressure and 
decrease in renal blood flow and glomerular filtration 
rate which was sustained throughout the angiotensin II 
infusion (Fig 16). There was no change in these 
parameters during vehicle infusion. All parameters 
returned to near control values after completion of the 



























C 60 120 180 240 
TIME (mins) 
Fig 16. Changes in glomerular filtration rate, renal 
blood flow and systemic blood pressure as a 
result of angiotensin II infusion (15 
ng /min /kg). 
* = P <0.05 for difference from saline control 
- - -- = angiotensin II infusion 
- saline infusion 
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2.2.2.2 Humoral factors 
Plasma angiotensin II increased by 3 -fold within one 
hour of starting the infusion, (p <0.01) (Fig 17), 
remained at the same level during the second hour, and 
then increased further during the third hour before 
returning to control values. Plasma renin activity was 
significantly decreased throughout infusion of 
angiotensin II. Plasma aldosterone also increased 
during the angiotensin II infusion. In contrast to 
other parameters, the level of aldosterone progressively 
increased during the course of the infusion and then 
returned to control values within one hour of the end of 
the infusion. The rate of urinary excretion of dinor 6 
keto PGF1a was unchanged during infusion of angiotensin 
II (Fig 18). Since there were significant changes in 
glomerular filtration rate during the angiotensin II 
infusion, the results have also been expressed as a 
fraction of the glomerular filtration rate. There was 
still no significant difference in excretion rate during 
the angiotensin II infusion. The plasma concentration 
of dinor 6 keto PGF1a was measured in 4 of the animals 
during infusion of angiotensin II and in 5 during the 
vehicle infusion (Fig 19). There was no change during 
infusion of either angiotensin II or vehicle although in 
one animal the plasma concentration was substantially 
higher than the others before infusion of vehicle. The 
urinary excretion rate of dinor 6 keto PGF1a was also 
high in this animal, which in part explained the 





















































60 120 180 240 
TIME (mins) 
Fig 17. Changes in plasma renin activity, angiotensin 
II and aldosterone as a result of angiotensin 
II infusion (15ng /min /kg) 
* = P <0.05 
** = P <0.01 for difference from saline control 
- - -- = angiotensin II infusion 
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C 60 120 180 240 
TIME (mins) 
Fig 18. Changes in rate of urinary excretion of dinor 6 
keto PGF1a also expressed as a function of 
glomerular filtration rate, as a result of 
angiotensin II infusion (15ng /min /kg). 
- - -- = angiotensin II infusion 
= saline infusion 
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Angiotensin II Infusion 
Pre Fbst 
Fig 19. Plasma concentration of dinor 6 keto PGF1a 
before and 30 minutes after infusion of 
angiotensin II (15 ng /min /kg) for 180 
minutes. Horizontal bar indicates mean value. 
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2.2.2.3 Renal excretory function 
There were no significant differences in urinary 
excretion of water, sodium or potassium between the dogs 















C 60 120 
TIME (rains) 
180 240 
Fig 20. Changes in urine flow, sodium excretion, and 
potassium excretion as a result of angiotensin 
II infusion (15 ng /min /kg). 
- - -- = angiotensin II infusion 
= saline infusion 
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2.3 Systemic and renal vascular sensitivity to 
angiotensin II in normotensive and hypertensive dogs. 
The results of the previous study suggest that in 
normotensive sodium replete dogs, systemic synthesis of 
PGI2 is not significantly altered by infusion of 
physiological quantities of angiotensin II. The same 
may not be true for renal PGI2, and moreover, the 
synthesis of other vasodilator prostaglandins such as 
PGE2 maybe stimulated by angiotensin II. As indicated 
in the introduction, other factors than prostaglandins 
may also modify the pressor response to angiotensin II, 
for example, there maybe changes in vascular sensitivity 
to angiotensin II. 
Some of these aspects of the actions of angiotensin 
II were further explored by comparing the systemic and 
renal effects of infusions of angiotensin II in 
conscious dogs before and 14 days after the development 
of one clip two kidney hypertension. Thirteen animals 
were used, 7 of which were studied when -hypertensive. 
2.3.1 Protocol and Special Methods 
A catheter was inserted into the bladder of each 
animal on the morning of the study, as described in the 
general methods section. A water diuresis was initiated 
by an intravenous infusion of 300 ml dextrose solution 
(50g /1) over 40 minutes and then maintained by infusion 
of dextrose solution (50g /1) containing PAH and inulin, 
via a Watson Marlow MHRE pump at 4 ml /min for the 
remainder of the study. Sodium chloride solution (150 
mmol /1) was infused intravenously at 0.5 ml /min via a 
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Harvard infusion pump. After a 90 minute equilibration 
period urine was collected for 2 successive 20 min 
control periods. Angiotensin II solution was then 
substituted for the sodium chloride solution and infused 
at 0.5 ml /min to give a final infusion rate of 5 
ng /min /kg body weight of angiotensin II. Urine was 
collected for 20 minutes. After a 20 minute recovery 
period, during which time sodium chloride solution was 
again substituted for angiotensin II, the same protocol 
was repeated with infusions of 10 and 15 ng /min /kg body 
weight of angiotensin II, each infusion being preceeded 
by a 20 minute control collection. Clearance results 
were calculated for each urine collection period. Blood 
pressure was monitored continuously throughout, and 
arterial blood samples were collected at the beginning 
and end of each urine collection. 
2.3. Results 
2.3.2.1 Normotension vs hypertension 
Blood pressure was sigificantly increased 14 days 
after partial occlusion of one renal artery (106.6+ 3.2 
- 133.5 + 4.5 mmHg, p < 0.01, n =7) and plasma renin 
activity was also significantly different in the two 
groups (3.0 + 0.2 vs 5.1 + 0.8 ng /ml /h, p<0.01, n =7). 
Urine flow, sodium excretion, effective renal plasma 
flow and glomerular filtration rate were all similar 
during the control period before and after induction of 
hypertension (Tables 2 and 3). The rate of urinary 
excretion of PGE was, however, significantly higher in 
the hypertensive compared with the normotensive animals 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.2.2 Angiotensin infusion in normotensive groups 
There were dose related increases in blood pressure 
during infusion of all three doses of angiotensin II 
(Table 2). At the same time there were dose related 
decreases in urine flow, sodium excretion and effective 
renal plasma flow. Glomerular filtration rate was only. 
significantly decreased during infusion of the two 
larger doses of angiotensin II. 
2.3.2.3 Angiotensin infusion in hypertensive group 
As in the normotensive group there were dose related 
increases in blood pressure with infusion of angiotensin 
II (Table 3), but neither effective renal plasma flow 
nor glomerular filtration rate were significantly 
altered. Urine flow also was not significantly changed 
(Table 3) but during the highest infusion rate of 
angiotensin II there was a significant increase in 
sodium excretion (p<0.05). 
2.3.2.4 Comparison between angiotensin infusion in 
normotensive and hypertensive groups. 
The differences have been summarised in Figs 21 -23. 
Increments in systemic blood pressure in response to 
angiotensin II were not significantly different in the 
two groups (Fig 21). The change in effective renal 
plasma flow during the 5ng /min /kg body weight infusion 
rate was significantly different with a decrease 
occurring in the normotensive group and small increase 
in the hypertensive group (Fig 22). The decrease in 
glomerular filtration rate during the 10 ng /min /kg body 
weight infusion was also greater in the normotensive 
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group as was the change in urine flow during the 15 
ng /min /kg infusions. The changes in sodium excretion 
were significantly different during both 10 and 15 
ng /min /kg infusions, a substantial decrease occurring in 
the normtensive group and increase in the hypertensive 












DOSE OF All 
(ng /min /kg body wt) 
Fig 21. Increment in mean blood pressure (BP) during 
infusion of different doses of angiotensin 
II. Results represent values during each 
preceeding control period subtracted from 
those during infusion period. 








DOSE OF All 
(ng /min / kg body wt) 
15 
Fig 22. Increment or decrement in effective renal 
plasma flow (RPF) andglomerular filtration 
rate (GFR) during infusion of different doses 
of angiotensin II. Results represents values 
during each preceeding control period 
subtracted from those during infusion period. 
- - -- = Normotensive 
= Hypertensive 
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DOSE OF QII 
(ng /min /kg body wt) 
15 
Fig 23. Increment or decrement in urine flow (V) and 
urinary sodium excretion (UNaV) during 
infusion of doses of angiotensin II. Results 
represent values during each preceeding 
control period subtracted from those during 
infusion period. 
- -- = Normotensive 
= Hypertensive 
= P <0.05 
= P<0.01 
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Although PGE excretion was significantly higher in 
the hypertensive group, further increases occurred 
during infusion of angiotensin II in both groups. The 
presence of haematuria in some animals limited the 
number of analyses which could be performed, and 
therefore clear cut dose dependent relationships could 
not be established for the increment in PGE excretion 
during angiotensin II infusion (Table 4). However the 
mean rate of excretion during angiotensin II infusions 
was significantly larger than the mean rate during the 
control periods in both normotensive (82 + 24 - 115 + 29 
pg /min, df =17, p <0.05) and hypertensive groups (255 + 66 
to 341 + 60 pg /min df =12, p<0.02). 
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TABLE 4. INCREMENT IN URINARY PGE EXCRETION (UpGEV) 
DURING ANGIOTENSIN II (ANG II) INFUSION 
Dose of ANG II 
(ng /min /Kg) 
UpGEV (Infuse -Control) 
(pg /min) 
Normotensive Hypertensive 
(n =7) (n =5) 
5 73.0 +25.0 38.0 +19.0 
10 20.0 +34.0 131.0 +93.0 
15 19.0 +24.0 174.0 +79.0 
UpGEV = Urinary prostaglandin E excretion 
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2.4 Interstitial cell morphology and the development of 
one clip - two kidney hypertension 
It is attractive to speculate that prostaglandins 
exert a modulatory role on vasoconstrictor systems in 
the kidney. Interstitial cells in the renal medulla 
certainly synthesise prostaglandins, in addition to 
other anti -hypertensive compounds. The dark osmiophilic 
granules in the interstitial cells appear to have an 
important function in this secretory role of the cells. 
The next study aimed to clarify the electron microscopic 
appearance of these granules and observe changes in 
their numbers in dogs with one clip - two kidney 
hypertension in an effort to correlate any changes with 
associated changes in renal prostaglandin synthesis. 
2.4.1 Protocol and Special Methods 
Sixteen female fox hounds (weight 16.0 to 27.0 kg) 
were used. The animals were divided into two groups. 
The hypertensive group consisted of 8 dogs that 
underwent surgery and subsequent partial clamping of a 
renal artery. The control group consisted of two dogs 
(Nos 5 and 13) that were surgically prepared as 
described, but in whom the clamp was not tightened and a 
further 6 dogs that did not undergo surgery. 
The kidneys from the two groups of animals were 
allocated into 1 of 3 categories. Kidneys from animals 
in the control group were designated normals. The 
kidneys from the hypertensive animals were divided into 
two further categories. The kidneys with a partially 
clamped renal artery were designated 'clamped' 
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kidneys and the opposite unclamped kidneys in the same 
animals were designated 'untouched'. All kidneys were 
weighed, halved coronally, and tissue blocks were 
dissected from the cortex and outer and inner medulla. 
The blocks were fixed in 3% glutaraldehyde (PH 7.4, 625 
mOsm /1) for 24 hours at 20 °C, postfixed in 3% osmium 
tetroxide for 2 hours at 4 °C and then embedded in 
Araldite. Initial screening of specially treated 1.5 um 
thick sections with light microscopy permitted areas in 
which all tubules were cut transversely to be chosen. 
500 A° sections from this area were floated onto 400 
mesh copper grids, stained with uranyl acetate and lead 
citrate, and examined on an AEI Corinth 275 electron 
microscpe (AEI Scientific Inst, San Diego, Calif). 
All granule counts were undertaken by a single 
observer (Ms J. Taylor) who was unaware of the origin of 
a particular section at the time of counting. The 
sections on the grid were scanned at low power, and the 
largest intact section chosen for counting. Each square 
of the copper mesh grid containing part of the section 
was viewed at 6000 x magnification. The number of 
granules in each complete interstitial cell was recorded 
and a minimum of 70 interstitial cells per medulla 
examined. 
2.4.2 Results 
2.4.2.1 Blood pressure monitoring 
As a result of technical problems with the arterial 
catheters, blood pressure recordings were only obtained 
from 6 of the animals in the hypertensive group. In 5 
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of these animals the mean blood pressure increased from 
101 + 2 mm Hg during the control period to 119 + 5 mmHg 
(p <0.02), an increase of 17 + 4 mmHg at the time of 
termination. The time course of the development of 
hypertension was different in each animal. Some animals 
showed a rapid initial rise in pressure with a 
subsequent small fall after some days, whereas other 
showed a gradual increase between the time of clamping 
and termination. The rise in blood pressure for the 
group was the same on the third day as at termination. 
In one dog (No 14) the renal artery was overclamped, 
and there was no change in blood pressure (95 + 1 mmHg 
before clamping and 97 + 2 mmHg after clamping). The 
two dogs in the control group in whom the clamp was not 
tightened had a mean blood pressure of 110 + 2 mmHg (No 
5) and 99 + 3 mmHg (No 13 ) at termination. 
Renal function assessed by estimation of plasma 
creatinine was normal in all 16 animals. 
2.4.2.2 Kidneys 
The kidneys were obtained a mean of 12 + 1.7 days 
after clamping. The mean weight of the clamped kidneys 
was 47 + 5 gms which was significantly less than the 
mean weight of the untouched kidneys (81 + 5 gms, 
p <0.005). Normal kidneys had a mean weight of 64 + 3 
gms, which was significantly greater than that of the 
clamped kidneys (p <0.05) but did not differ 
significantly from the weight of the untouched kidneys. 
2.14.2.3 Light microscopy 
Sections of renal cortex and medulla were initially 
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scanned by light microscopy. There were no gross 
morphological abnormalities in any of the kidneys. The 
impression was that there were increased numbers of 
cells in clamped kidneys compared with normal and 
untouched kidneys, but little difference between 
untouched and normal. Quantification of the numbers of 
interstitial cells in the medullae of the three groups 
could not be attempted by light microscopy for two main 
reasons. First, difficulties in accurate cell 
identification by this method are considerable. Second, 
the distribution of interstitial cells throughout the 
medulla may not be uniform and accurate identification 
of the original location of a tissue block after 
processing is difficult; this would make it impossible 
to be sure that comparable areas in different kidneys 
were being counted. 
2.4.2.4 Electron microscopy 
The medullary interstitial cell is a stellate cell, 
often ill- defined with one or more cytoplasmic 
processes, and frequently closely applied to adjacent 
capillaries or tubules (Fig 24). The cytoplasm of the 
cell has a characteristic lacey appearance due to 
dilated rough and smooth endoplasmic reticulum. The 
osmiophilic granules are located mainly in the 
perinuclear region or clustered in the cytoplasm. The 
dark type have a granular appearance, are membrane 
bound, and are smaller than the light granules (Fig 25, 
26). The light granule is a large homogeneous structure 
that is not bound by a membrane and is less electron 
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dense than the dark granule. Both types of granule were 
observed apparently being extruded from cells (Fig 25, 
26), suggesting that the granule contents may not be 
released within the interstitial cells. There appeared 
to be an inverse relationship between the presence of 
cisternae and the prevalence of granules within the 
cell. Collagen fibres were often present around the 
cells, and in certain sections intracellular fibrillar 
material was seen, virtually always in cytoplasmic 
processes, extracellular fibres being closely related to 
the overlying plasma membrane (Fig 27). The amount of 
collagen present in the sections was surprising, 
particularly when compared with the amount present 
around interstitial cells from other species. Its 
presence was, however, a consistent feature in sections 
both from the normal and hypertensive animals. 
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Fig 24. Clamped kidney: inner medulla. Interstitial 
cell containing numerous dark granules and 
mitochondria. The cell is close to an 
adjacent basement membrane (arrow) of a 
tubule, and the surrounding interstitial space 
shows abundant collagen (x8000). 
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Fig 25. Untouched kidney: inner medulla. Three light 
granules and one dark granule lie near the 
plasma membrane of this interstitial cell. 
One light granule is in the process of being 
extruded from the cell (arrow). The cytoplasm 
around these granules contains dilated rough 
endoplasmic recticulum (x20,000). 
99 
Fig 26. Clamped kidney: inner medulla. In this cross 
section of an interstitial cell process three 
dark granules are present in the cytoplasm. 
Several dark granules are seen apparently in 
the process of extrusion (arrow) (x20,000). 
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Fig 27. Normal kidney: inner medulla. In this 
interstitial cell process intracellular 
fibrils can be seen lying parallel to the 
plasma membrane, and extracellular collagen 
fibres are apparently attached to the membrane 
and at right angles to it. Clumps of these 




Numbers of cells could not be accurately counted on 
electron microscope sections, because of the high 
magnification involved and the impossibility of ensuring 
that sections from comparable sites in all groups of 
kidneys were being assessed. 
The total number of granules per interstitial cell 
was different in the three groups (Fig 2b). The number 
of dark granules per cell in clamped kidneys (4.69 
+0.50) was significantly greater than in the normal 
kidneys (0.63 +0.12, p <0.01), whereas the count in the 
untouched kidneys (0.14 + 0.04) was significantly less 
than in both the contralateral clamped kidneys and in 
normal kidneys (p <0.01). The proportion of light and 
dark granules in interstitial cells from kidneys in each 
group are shown in Fig 29. The proportion of dark 
granules (95.3 %) in the clamped kidneys was 
significantly greater than in the untouched kidneys 
(31.1%, p<0.001), whereas the proportion of dark 
granules in normal kidneys (79.5 %) was significantly 
higher than that in the untouched kidneys and lower than 
that in the clamped kidneys (p <0.001 in each case). 
There were fewer light granules per cell in the 
clamped kidneys (0.23 + 0.05) than in the untouched 
kidneys (0.44 + 0.15), but the difference was not 
significant. There was, however, a significantly larger 
number of light granules per cell in the untouched 
kidneys than in normal kidneys (0.16 + 0.04, p<0.01). 








per cell in either kidney and the extent of blood 
pressure elevation in individual dogs. 
NUMBER OF GRANULES PER INTERSTITIAL CELL 
= DARK GRANULES 
= LIGHT GRANULES 
1 3 4 5 6 13 15 16 17 18 
NORMAL 
2 7 8 9 10 11 12 14 
CLAMPED 
2 7 8 9 10 11 12 14 
UNTOUCHED 
Fig 28. Number of granules per interstitial cell in 













PERCENTAGE OF DARK AND LIGHT GRANULES IN INTERSTITIAL CELLS 
n 1 
= DARK GRANULES 
= LIGHT GRANULES 
i i 
3 4 5 6 13 15 16 17 18 2 7 8 9 10 11 12 14 2 7 8 9 10 11 12 14 
NORMAL CLAMPED UNTOUCHED 
Fig 29. Relative proportions of dark and light granules 
ininterstitial cells in sections from normal, 
clamped and untouched kidneys. 
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3. STUDIES IN MAN 
The following studies are described in this section: - 
3.1 The renin angiotensin system, PGI2 and dietary 
sodium intake. 
3.2 Prostaglandins and the renal response to isotonic 
sodium chloride infusion. 
3.3 Systemic PGI2 synthesis and the surgical correction 
of hypertension in Conn's syndrome. 
The extrapolation of experimental results obtained 
in vitro to derive explanations for physiological and 
pathological events in man is an attractive scientific 
exercise. Proof of the validity of such hypotheses is 
always difficult to obtain. The many possible 
interactions between prostaglandins, sodium balance and 
the state of the renin angiotensin system provides a 
typical example of such a situation. The next series of 
studies were designed to provide information to help 
define these interactions more clearly in normotensive 
and hypertensive man. All of these investigations were 
carried out with the informed consent of the individuals 
involved and the protocols employed had been approved by 
the Ethical Review Committees of the respective 
institutions. 
3.1 The renin angiotensin systems PGI2 and dietary 
sodium intake. 
The renin angiotensin system is activated in normal 
man during periods of dietary sodium restriction. If 
PGI2 was implicated in this process, either by increased 
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renal synthesis promoting renin release, or by increased 
vascular PGI2 synthesis in response to increased 
circulating concentrations of angiotensin II, then an 
increase in excretion of its major urinary metabolite 
dinor 6 keto PGF1a, might be expected. 
3.1.1 Protocol and Special Methods 
Ten healthy male volunteers (age 26 -32 years) were 
included in this study at Vanderbilt University. They 
progressed through the dietary periods in random order. 
Three different diets were used with a sodium content of 
10 mmol per day (low), 150 mmol per day (normal), and 
300 mmol per day (high). The potassium content of each 
diet was constant (60 mmol per day ). Each subject took 
a particular diet for a preliminary four day period and 
continued to take it for a further three days, during 
which time 24 hour collections of urine were made. The 
subjects remained fully ambulant during this period, but 
on the final day of the study they lay recumbant for two 
hours. Blood pressure was then checked and blood drawn 
for measurement of plasma renin activity, aldosterone 
and angiotensin II. A two -week washout period 
intervened between the diets. 
3.1.2 Results 
The rate of urinary excretion of sodium and potassium 
derived from the 24 hour urine collections corresponded 
to the predicted dietary intake (Table 5). The blood 
pressure of volunteers was less than 130/90 mmHg supine 
at entry to the study and did not significantly differ 
at the end of the three dietary regimes. Both plasma 
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TABLE 5. URINARY ELECTROLYTES AND MEAN ARTERIAL PRESSURE DURING 
VARIED DIETARY SODIUM INTAKE 
Predicted dietary Na+ 
(mM /24 h) 
10 150 300 
Actual urinary Na+ 
(mM /24 h) 
7.4 +2.4 133 +15 239 +44 
Actual urinary K+ 
(mM /24 h) 
57 +7 72 +9 60 +9 
Mean arterial pressure 
(mm Hg) 
110 +3.5 108 +5.4 108 +6.7 
Urinary Na+ excretion significantly differed between diets by analy- 
sis of variance (P <0.01). The variation in urinary K+ excretion and 
mean arterial pressure did not attain statistical significance. 
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renin activity and plasma angiotensin II concentrations 
were significantly increased by low sodium intake 
(p <0.01) but there was no significant difference between 
the levels on normal and high sodium intake. The 
excretion of 2, 3 dinor 6 keto PGF1a was highest on the 
normal sodium intake, although the difference between 
the levels on normal and high sodium intake did not 
attain significance (Fig 30). By contrast, excretion 
during sodium restriction was significantly lower (P < 
0.01) at a time when both plasma renin activity and 
angiotensin II were substantially increased. 
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DIETARY SODIUM INTAKE AND THE RELATION BETWEEN 
PLASMA RENIN ACTIVITY (PRA) ANGIOTENSINE AND DINOR 




6 KETO PGFIe, 
















40 80 120 160 200 240 280 
UNAV (mM/day) 
Fig 30. Changes in urinary excretion of dinor 6 keto 
PGF1a, plasma angiotensin II and plasma 
renin activity (PRA) as a function of 24 hour 
urinary sodium excretion in normal subjects 
on three different dietary sodium intakes. 
Dinor 6 ketoPGF1a and sodium were measured in 
the same 24 hour urine specimens. 
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3.2 Prostaglandins and the renal response to isotonic 
sodium chloride infusion 
Restriction of dietary sodium intake as well as 
activating the renin angiotensin system, also leads to a 
contraction of the extracellular fluid volume. An 
alternative approach to examining the interrelationship 
between prostaglandins and sodium excretion is to 
observe the effects of expansion of the extracellular 
fluid volume. In the next study extracellular volume 
was acutely expanded by rapid intravenous infusion of 
isotonic sodium chloride solution in normal man. 
Changes in renal excretion of PGE and dinor 6 keto PGF1a 
were monitored, and the effects of inhibition of 
prostaglandin synthesis with indomethacin observed. 
3.2.1. Protocol and Special Methods 
Studies were carried out on ten normal human male 
subjects, mean age 30 years. All subjects ate an 
unrestricted diet and were requested to refrain from 
sexual intercourse for at least 24 hours before the 
study. Urine was collected for the 24 hours up to 2200 
hours on the evening before the study. Subjects then 
fasted and were requested not to smoke. At 0800 hours 
the next morning a catheter was inserted into a vein in 
the antecubital fossa of each arm, a sample of blood was 
obtained, and an intravenous infusion of dextrose 
solution containing PAH and inulin was started at a rate 
of 1 ml /min, after suitable loading doses of each 
compound. Between 1000 hours and 1100 hours an 
intravenous infusion of sodium chloride solution (150 
110 
mmol /1) was given at a rate of 50 ml /min (3 litres in 
total) and the subjects remained supine until 1300 hours 
except for rising to pass urine. Blood and urine 
samples were collected at timed intervals of 
approximately 30 minutes throughout the study. Blood 
pressure was measured with the subject recumbant, before 
each blood sample was taken. Additional blood samples 
for the measurement of plasma renin activity were 
collected immediately before and after infusion of 
sodium chloride and again two hours later at the end of 
the study. In the studies with indomethacin (50 mg) 140 
umol of the drug was taken by mouth at 2200 hours on the 
evening before the study and a similar dose at 0830 
hours on the day of the infusion. 
The results of each study were accummulated into 
three separate periods. Period 1 was a 1 hour control 
period preceeding sodium chloride infusion. Period II 
was from 1000 -1130 hours, including 1 hour during the 
sodium chloride infusion and the next half hour. Period 
III was the final one and half hours of the study. 
Prostaglandins were measured in the last urine collected 
from each subject during each of the three periods. 
Mean blood pressure was calculated as diastolic 
pressure + (pulse pressure - 3) and the results given 
are the mean of at least three separate estimations on 
each individual during each period. 
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3.2.2 Results 
3.2.2.1 Sodium chloride infusion without indomethacin 
pre- treatment. 
3.2.2.1.1 Systemic blood pressure 
Mean blood pressure was not altered significantly by 

























































































































































































































































































































































































































































































































































































































































































































































































































































3.2.2.1.2 Renal function 
Effective renal plasma flow decreased significantly 
between period II (921 + 88 ml /min) and period III (813 
+ 72 ml /min, p<0.01) to a value not significantly 
different from period 1 (Table 6). 
Glomerular filtration rate did not change 
significantly throughout the study period (Table 6). 
There was great individual variability in the maximum 
rate of urine flow achieved during period II (1.0 - 
12.4 ml/min;), and this was associated with a similar 
wide variation in the rate of sodium excretion. Two of 
the subjects showed no change in the rate of sodium 
excretion during period II whereas others showed very 
large increments (Fig 31). The percentage of the 
infused solution which was excreted within two hours 
after the end of the infusion of sodium chloride varied 
between 17 and 100% for different indiviudals. Free 
water clearance increased significantly during period II 
(p <0.05) but had returned to values below control by 
















I II IQ 
Period 
I II 
Fig 31. Values in individual subjects for urine flow, 
sodium excretion and free water clearance 
before (I), immediately after (II) and 90 
minutes after (III) infusion of three litres 
of sodium chloride solution. Each column of 
results refers to pre -treatment with ( +IND) 
or without ( -IND) indomethacin. 
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3.2.2.1.3 Plasma renin and urinary prostaglandins 
Plasma renin activity decreased significantly between 
periods I and II (p <0.01) and remained suppressed at 
the end of period III (Fig 32). Excretion of PGE 
during the day before the study (1.17 + 0.21 nmol /24) 
showed no correlation with either the sodium content of 
the urine during the same period (166 + 15 mmol /24) 
(r =0.10, p >0.05) or with the subsequent rate of 
excretion of infused sodium chloride solution, as 
indicated by the percentage of the infused sodium 
chloride solution that had been excreted by the end of 
period III (r =0.54, p >0.05). There was no relationship 
between the rate of excretion of the infused sodium 
chloride solution and the excretion of sodium over the 
the 24 hours before the study (Fig 33). The rate of 
excretion of PGE decreased significantly between the end 
of period 1 and the end of period III (Fig 34) 
(p <0.05). Urinary PGE excretion decreased during period 
II, the concentration of PGE in the urine being below 
the reliable limit of detection in all samples. 
Excretion of dinor 6 keto PGF1a was higher after 
infusion of sodium chloride (period II) than during the 
control period 1, although the difference narrowly 
failed to achieve significance. Excretion during period 
III was significantly lower than that during period II 
(p <0.05, Fig 32). The rate of excretion of dinor 6 keto 
PGF la did not correlate with glomerular filtration, 
urine flow or sodium excretion although there was a weak 













Fig 32. Plasma renin activity and urinary excretion of 
dinor 6 keto PGF1a (expressed as a function of 
glomerular filtration rate) before and 
immediately after sodium chloride infusion 
(periods I and II) and again 90 minutes later 
(period III). 
# = p<0.05 
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Fig 33. Percentage of the infused sodium load that was 
excreted within 120 minutes of completing the 
sodium chloride infusion, expressed as a 
function of urinary sodium excretion over the 









Fig 34. Rate of urinary PGE excretion over 30 mins 
before sodium chloride infusion (I) and 
during a 30 min collection starting90 mins 
after completion of the sodium chloride 
infusion (III). 
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3.2.2.2 Sodium chloride infusion with indomethacin 
pre- treatment 
3.2.2.2.1 Systemic blood pressure 
There was no significant change in mean blood 
pressure during the infusion of sodium chloride 
solution, the blood pressure being the same as in the 
control experiments (Table 6). 
3.2.2.2.2 Renal function 
As in the control studies, effective renal plasma 
flow decreased significantly between period II (741 + 49 
ml /min and period III (684 + 39m1 /min, p <0.02). 
Effective renal plasma flow was significantly lower 
during each period after indomethacin compared with the 
values obtained in the control experiment (Table 6). 
Glomerular filtration rate was again unaltered by 
infusion of sodium chloride and the value during each 
period was not significantly different in the studies 
with and without indomethacin (Table 6). The patterns 
of increased urine flow were similar, but the actual 
rates of urine flow were significantly lower during the 
first two periods p <0.05) with indomethacin pre- 
treatment (Fig 35). In most subjects there was a 
substantial increase in sodium excretion between periods 
1 and II (Fig 31), however, the further increment in 
sodium excretion between periods II and III was 
significantly less with indomethacin (p <0.02, Fig 31). 
Free water clearance was again significantly increased 
(p <0.05, Fig 31) but the results did not differ 













Fig 35. Difference in rate of urinary sodium excretion 
during period II and period III in normal 
subjects with ( +IND) and without ( -IND) pre- 
treatment with indomethacin. 
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3.2.2.2.3 Plasma renin activity and urinary PGE 
There was again a significant decrease in plasma 
renin activity between periods I and II (p <0.05, Table 
6) although the values were not significantly different 
with and without indomethacin. The concentration of PGE 
in the urine was below the reliable limit of detection 
in all but one subject. 
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3.3 SLstemic PGI2 sLnthesis and the surLical 
correction of hypertension in Conn's Syndrome. 
The potent vasodilator activity of PGI2 suggests an 
important potential role as an antihypertensive 
factor, particularly if sufficient quantities are 
synthesised to affect peripheral vascular resistance. 
This possibility was examined in a small group of 
patients with hypertension due to primary 
hyperaldosteronism. By studying them before and after 
removal of an adrenal adenoma it was also possible to 
further examine the effect of changes in activity of the 
renin angiotensin system on systemic PGI2 synthesis. 
3.3.1 Protocol and Special Methods 
Five women with primary hyperaldosteronism were 
studied (age 35 -66: mean 49 years). In th pre- operative 
period each patient was maintained on a dietary sodium 
intake of 100 mmoles /day and blood pressure was 
monitored every four hours. After at least three days, 
24 hour urine collections were made and blood was drawn 
for measurement of plasma renin activity and aldosterone 
after overnight bedrest (supine), and again after 
standing or walking for two hours (upright). In each 
patient an adrenal adenoma was removed at a subsequent 
operation. Three weeks later the patients were again 
given the same diet and further recordings of blood 




Plasma aldosterone was increased in all patients pre- 
operatively and in every instance was lower within three 
weeks of removal of the adenoma (Fig 36). Similarly, 
all patients had a low plasma potassium pre -operatively 
which was corrected by surgery. Removal of the adenoma 
provoked a substantial increase in activity of the renin 
angiotensin system as shown by the increase in plasma 
renin activity, yet systolic and diastolic blood 
pressure fell significantly. After operation, excretion 
of dinor 6 keto PGF la decreased in all of thepatients 
from the pre- operative level (Fig 37). Creatinine 
clearance was not significantly modified by removal of 
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Fig 36. Systolic ( ) and diastolic ( - --) blood 
pressure, plasma potassium, plasma renin 
activity (PRA) and plasma aldosterone 
concentration (PAC) before and three weeks 
after removal of an aldosterone secreting 
adenoma. Horizontal bars represent mean 
values for the group. 
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PRIMARY HYPERALDOSTERONISM - BEFORE AND AFTER 
REMOVAL OF THE ADENOMA 
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Fig 37. Dinor 6 keto PGF1a excretion in 24 hour urine 
collections made before and again 3 weeks 
after removal of an aldosterone secreting 
adenoma. Horizontal bars represent mean 




The development of reliable methods for quantitative 
analysis of prostaglandins in biological fluids has been 
a difficult and controversial area of research. The 
technique of mass spectrometry has been of major 
importance in this research. Its initial application 
was in the studies of Bergstrom and colleagues on the 
structure of prostaglandins (Bergstrom, Ryhage, 
Samuelsson and Sjovall 1963); subsequently it was 
developed for quantitative analysis (Morton 1972). 
Indeed the technique has been the yard stick by which 
the validity of other methods of analysis have been 
assessed. Various factors have limited its widespread 
use. The instrumentation is expensive, complex and 
requires the services of skilled maintenance and 
operating staff. Internal standards are required to 
permit corrections to be made for losses of compound 
during extraction from biological fluids. By far the 
most satisfactory standards are derivatives of the 
molecule under study in which 3 or 4 of the protons have 
been replaced by deuterium atoms. Such molecules are 
difficult and expensive to synthesise and are thus 
limited in availability. Finally the sensitivity of the 
electron impact method of mass spectrometry is such that 
large amounts of compound have to be extracted from 
biological fluids to provide sufficient for analysis. 
Contamination of the sample to be analysed is a major 
127 
problem and time consuming methods of extracting and 
purifying prostaglandins from the biological samples 
have to be employed. When correctly applied the method 
does however provide a precise means of quantitative 
analysis. 
Development of negative ion chemical ionisation mass 
spectrometry has lead to significant improvements in the 
sensitivity of detection of the system. Chemical 
ionisation using positive ion detection has been used 
for some time (Suzuki, Morita, Kawamura, Murota, 
Nishizawa, Miyatake, Nagase, Ohno and Shimizu 1980) but 
only recently have the advantages of the negative ion 
technique been realised (Dougherty 1981). The technqiue 
is not only an order of magnitude more sensitive than 
the electron impact method in most instruments, but the 
ion to be monitored is also usually of higher molecular 
weight, therefore reducing contamination by interfering 
signals from low molecular weight ions. Employing this 
method, analysis of one of the metabolites of 
prostaglandin I2, as described in the methods section, 
has been particularly successful. The volume of 
biological sample which has to be extracted has been 
substantially reduced, eg. 5 mls of urine is often 
sufficient. Moreover exploitation of the chemical 
properties of 2, 3 dinor 6 keto PGF1a, ie. its ability 
to form a complete lactone under acid conditions has 
meant that a series of organic extractions followed by 
thin layer chromatography provides a sample that can be 
applied directly to the gas chromatography column 
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attached to the mass spectrometry system. This has 
meant that precise analyses can be quickly obtained on a 
comparatively large number of samples. 
Until the development of this methodology, 
radioimmunoassay provided the only reliable means of 
achieving such results. Indeed this is still by and 
large the case for most compounds that do not lend 
themselves to such easy extraction from biological 
fluids as 2,3 dinor 6 keto PGF1a. Radioimmunoassay 
relies on the availablity of specific antibodies to the 
compound of interest. The only antibody used for the 
current studies is both specific and sensitive for 
PGE1and PGE2( Dray, Charbonel and Maclouf 1975). PGE2 
is the dominant renal prostaglandin but wherever 
immunoassay measurements have been employed the more 
general term PGE has been used. Prior extraction of the 
prostaglandin from biological fluid is required, but the 
C18 microcolumns described have proved satisfactory. 
The demonstration of linearity with respect to the 
amount of PGE detected after extraction of differing 
volumes of urine, and also after addition of different 
amounts of PGE2 suggests that the assay is reliable. 
Whilst mass spectrometric analysis of PGE2 in urine 
is possible (Frolich, Wilson, Sweetman, Smigel, Nies, 
Carr, Watson and Oates 1975), a number of time consuming 
purification steps must be employed, including high 
performance liquid chromatography. This severely limits 
the number of samples that can be analysed, and overall 
provides little advantage over a reliably validated 
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radioimmunoassay system. 
A number of different methods have been used for 
assessing renal synthesis of the two different 
prostaglandins. Measurement of the concentration of PGE 
in renal venous plasma provides a useful measure of 
renal PGE synthesis (Beckman and Zehr 1975). The rate 
of renal PGE synthesis assessed by this method is 
different from that calculated from measurement of PGE 
in urine but various manipulations that interfere with 
renal PGE synthesis cause parallel changes in the rates 
of production derived from both urine and renal venous 
plasma (Dunn, Liard and Dray 1978). The advantages of 
measuring concentrations of PGE in renal venous plasma 
is that the results are not subject to some of the 
difficulties of interpretation that occur in assessing 
changes in urinary excretion rates (see later). The 
disadvantage is that renal plasma flow should be 
measured if production rates are to be calculated. 
Moreover release of PGE2 by platelets during the passage 
of blood along the renal venous catheter may result in 
appearance of spuriously high levels of PGE in the 
plasma. Measurement of PGE2 in urine has a number of 
attractions, in particular it does appear to reflect 
renal PGE2 synthesis (Frolich, Wilson, Sweetman, Smigel, 
Nies, Carr, Watson and Oates 1975). A number of factors 
however complicate interpretation of the significance of 
changes in urinary PGE excretion. Urine flow is 
undoubtedly an important determinant of PGE excretion 
(Kirschenbaum and Serros 1980, Kaye, Zipser, Hahn, Zia 
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and Horton 1980, Kaye, Zipser, Wright, Rosenblatt and 
Lifschitz 1 981 ), although there is not always a 
proportionate relationship between the two parameters 
(Bowden, Ware, Demets and Keiser 1977). Urinary pH may 
also influence PGE excretion rates since it is a weak 
acid with a pk of approximately 6.5 (Haylor Lote and 
Thewles 1984), however in most of the studies described 
there are unlikely to be major changes in urinary pH. 
Any contamination of urine with blood or semen will also 
invalidate the results (Patrono, Wenmalm,Ciabattoni, 
Nowak, Pugliese and Cinotti 1979) as will delays in 
storage at low temperature. 
Interpretation of the significance of changes in 
excretion of dinor 6 keto PGF1a is less prone to 
errors. The compound is stable in urine and its 
excretion is independent of urine flow rate. Its 
limitation however is that it only permits 
interpretation of systemic changes in PGI2 synthesis, 
rather than selective renal changes (Fitzgerald, Brash, 
Falardeau and Oates 1981). There is also the 
theoretical possibility that changes in liver and renal 
blood flow may significantly alter rates of beta 
oxidation, thereby interfering with formation of the 
metabolite. There is at present no good evidence to 
support such a hypothesis. 
Despite these reservations and limitations, useful 
conclusions on the role of both prostaglandin E2 and I2 
in controlling sodium excretion, renal and systemic 
vascular resistance can be made from the various studies 
131 
described. 
These studies explore a variety of possible roles for 
prostalgandins E2 and I2 in both modulating renal 
sodium excretion and renal and systemic vascular 
responses to a variety of vasoconstrictor stimuli. 
Particular attention has been directed at assessing the 
relationship between the prostaglandins and the renin 
angiotensin system. At the same time the models used 
also permit some more general conclusions to be drawn 
about the inter -relation between sodium balance and the 
state of the cardiovascular system. 
2. The development of renal hypertension 
The first study examined factors important in the 
development of the established phase of one clip two 
kidney hypertension. Accumulation of fluid during the 
early phase of increased blood pressure in experimental 
renal hypertension has been previously documented 
(Bianchi, Baldoli, Lucca and Barbin 1972; Watkins, 
Davis, Hanson,Lohmeir and Freeman 1976; Rocchini and 
Barger 1979), although it seems to be less pronounced 
during the development of one clip two kidney 
hypertension compared with one clip one kidney 
hypertension (Bianchi, Tenconi and Lucca 1970; Liard, 
Cowley McCaa, McCaa and Guyton 1974). The rapid 
increase in body weight of the animals in the present 
studies 1 -3 days after clamping was almost entirely 
due to fluid retention although formal metabolic balance 
studies were not undertaken. The plasma sodium 
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concentration remained constant during the increase in 
weight, indicating that sodium and water were retained 
in proportion to maintain isotonicity and were therefore 
evenly distributed between the interstitial space and 
the plasma. If it is assumed that extracellular fluid 
volume is equal to 20% of the body weight at the end of 
the control period, this implies that the estimated 
extracellular fluid increased by 11% between days 1 and 
3. The plasma volume increased by 13 %, as calculated 
from the fall in PCV during this period suggesting that 
even distribution of the accumulated fluid between 
plasma and interstitial space had indeed occurred. 
The rise in plasma renin acitvity during the same 
period is comparable with the rise in other studies of 
one clip two kidney hypertension (Bianchi, Baldoli, 
Lucca and Barbin 1972, Watkins, Davis, Hanson, Lohmeir 
and Freeman 1976; Maxwell, Lupu, Viskoper, Aravena and 
Waks 1977) and is compatible with the hypothesis that 
the early phase of hypertension in this model is 
angiotensin dependent (Caravaggi, Bianchi, Brown, Lever, 
Morton, Powell- Jackson, Robertson and Semple 1976). 
Under normal circumstances the development of the 
established phase (Phase 2) of renal hypertension 
(Brown, Cuesta, Davies, Lever, Morton, Padfield, 
Robertson, Trust, Bianchi and Schalekamp 1976) is 
associated with a decrease in plasma renin activity to 
normal or only slightly elevated levels (Bianchi, 
Baldoli, Lucca and Barbin 1972). At this stage the 
persistent elevation of blood pressure is unlikely to be 
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accounted for by the immediate vasoconstrictor actions 
of angiotensin II (see later) and there is only a small 
decrease in blood pressure after inhibition of the 
actions of angiotensin II (Watkins, Davis, Hanson, 
Lohmeir and Freeman 1976; Masaki, Ferrario, Bumpus, 
Bravo and Khosla 1977). Sodium restriction in both 
normotensive dogs and in those with established 
hypertension alters the pattern completely. Although 
the level of blood pressure does not change there is an 
increase in plasma renin activity and the blood pressure 
becomes dependent on the immediate vasoconstrictor 
actions of angiotensin II, as shown by the decrease in 
blood pressure immediately after infusion of angiotensin 
II antagonists (Watkins, Davis, Hanson, Lohmeir and 
Freeman 1976; Liang, Gavras and Hood 1978). Sodium 
restriction at the time of partial occlusion of a renal 
artery does not prevent the development of hypertension, 
at least in the one clip, one kidney model (Brown, 
Davis, Olichney and Johnston 1966; Conway 1968), 
although very large increases in plasma renin activity 
may occur (Fray, Johnson and Barger 1977) presumably 
reflecting changes in smooth muscle or receptor 
sensitivity to angiotensin II (Brunner, Chang, Wallace, 
Sealey and Laragh 1972; Strewler, Hinrichs, Guiod and 
Hollenberg 1972). In the present study plasma renin 
activity and aldosterone remained at a constant level 
between days 3 and 8 during the period of low sodium 
intake, while there was only a small decrease in mean 
blood pressure. The factors responsible for the 
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transition from the early renin dependent phase (phase 
I) to phase 2 of renal hypertension are unclear at 
present. It has been suggested that a transient period 
of sodium retention in the early phase of renal 
hypertension in the dog is important in mediating the 
fall in plasma renin activity and the development of the 
long acting vasoconstrictor action of angiotensin II 
(Brown, Cuesta, Davis, Lever, Morton, Padfield, 
Robertson, Trust, Bianchi and Schalekamp 1976). The 
data obtained from our study are consistent with this 
hypothesis in that plasma renin activity only decreased 
on restoration of a high sodium intake. 
It has been postulated by Ledingham and Cohen (1964) 
that the fluid accummulation in the early period after 
partial occlusion of a renal artery causes an increase 
in cardiac output and subsequent maintenance of 
hypertension as a result of 'whole -body autoregulation'. 
The accummulated fluid is, however, clearly not required 
for the initial elevation of blood pressure, since 
hypertension develops in the one kidney animal despite a 
very low dietary intake of sodium (Brown, Davis, 
Olichney and Johnson 1966; Conway 1968) and as shown, 
in the experiments reported here acute removal of the 
retained fluid does not result in an immediate decrease 
in blood pressure. 
The factors inducing the fluid retention have not 
been clearly defined. There was a significant increase 
in plasma aldosterone by day 3. Although this is 
presumably secondary to the increase in concentration of 
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angiotensin II in the plasma, the rise appears to occur 
more slowly than the increases in plasma renin activity 
that were measured. A sodium retaining action of 
angiotensin II acting within the kidney may also be 
important (Lohmeir, Cowley, Trippodo, Hall and Guyton 
1977). 
The effect of renal artery occlusion on cardiac 
output remains controversial (Ferrario and Page 1978). 
Bianchi et al (1972) were able to demonstrate an 
increase in cardiac output during the early phase of 
renal hypertension, whereas Korner, Anderson, Johnson, 
Angus and Fletcher (1978) suggested that the changes in 
cardiac output in the early phase of hypertension play 
no role in the development of hypertension. Changes in 
heart rate have also been variously reported (Bianchi, 
Baldoli, Lucca and Barbin 1972; Masaki, Ferrario, 
Bumpus, Bravo and Khosla 1977) but in the present study 
there was a significant fall in heart rate between days 
1 and 3 which is presumably a result of a reflex 
response initiated by stimulation of the baroreceptors 
after the rise in systemic blood pressure (Liard, 
Cowley, McCaa, McCaa and Guyton 1971). The subsequent 
increase in heart rate during the low dietary sodium 
period probably reflects adaptation of the baroreceptor 
reflexes to the elevated blood pressure. Although no 
direct measurements of cardiac output were made, the 
product of heart rate and pulse pressure provides an 
approximate index of cardiac output. These results 
would suggest that there is a fall in cardiac output 
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during the early period after induction of hypertension 
with the increase in blood pressure being entirely 
accounted for by an increase in peripheral resistance. 
3. Prostaglandin E and sodium excretion in renal 
hypertension 
Acute infusion of PGE2 into the kidney has a 
natriuretic action (Vander 1968), whereas long term 
infusions of PGE2 into the kidneys of conscious animals 
result in an early natriuresis followed by a significant 
rise in blood pressure over several days as a result of 
increased renin release from the kidney (Hockel and 
Cowley 1980). Conversely, sodium restriction increases 
renal production of PGE in the rabbit (Stahl, Attallah, 
Bloch and Lee 1979). In a previous study on one clip 
two kidney hypertension in conscious dogs, results 
suggested that there is an increase in the concentration 
of PGE in renal venous blood from the intact kidney 
after the early phase of hypertension, associated with 
the spontaneous excretion of retained sodium and water 
(Dighe, Smith, Ungar and Whelpdale 1978). In the 
study described here the accumulated salt and water was 
removed by dialysison day 3. The failure of the 
concentration of PGE in renal venous blood to increase 5 
days after induction of hypertension (Dighe, Smith, 
Ungar and Whelpdale 1978) implies that the PGE released 
after the early phase of hypertension by the untouched 
kidney, is involved in sodium excretion, and would be 
consistent with the suggestion that PGE produced within 
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the kidney exerts a natriuretic action, and that its 
release from the intact kidney is triggered by the 
retention of sodium and water. 
4. Factors determininE vascular sensitivity to 
angiotensin II 
As already discussed, vascular sensitivity to 
angiotensin II maybe markedly altered by changes in 
sodium balance. The mechanism of the apparent 
tachyphalaxis to infused angiotensin II, for example 
under conditions of sodium depletion, is controversial 
(Reid and Laragh 1965), but release of vasodilator 
prostalgandins may be important. Studies in 
anaesthetised animals have demonstrated that the renal 
vasoconstriction caused by infusion of angiotensin II 
into the kidney is partially opposed by the release of 
vasodilator prostaglandins (McGiff, Crowshaw, Terragno 
and Lonigro 1970; Aiken and Vane 1973). Two more recent 
studies particularly implicate PGI2 as the vasodilator 
released by angiotensin II in both the renal and 
mesenteric vasculature (Shebuski and Aiken 1980; 
Dusting, Mullins and Doyle 1980). Care must be taken in 
extending such observations to conscious unstressed 
animals in which circulating concentrations of 
angiotensin II are very low. In both studies very large 
doses of angiotensin II were infused and the surgical 
trauma inherent in such studies stimulates renal 
prostaglandin synthesis (Terragno, Terragno and McGiff 
1977). Evidence that vasodilator prostaglandins 
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modulate the vasoconstrictor activity of angiotensin 
II in the systemic circulation is even less clear. 
Aiken and Vane were unable to demonstrate any effect of 
indomethacin on angiotensin II induced vasoconstriction 
in the isolated hind limb of dogs (Aiken and Vane 1973). 
However, inhibitors of prostaglandin synthetase have 
been reported to increase the pressor response to 
infused angiotensin II in man (Negus, Tannen and Dunn 
1976; Vierhapper, Waldhaus and Nowotny 1981). 
In experiments described here the role of PGI2 as a 
systemic modulator of angiotensin II activity was 
investigated by infusion of low doses of angiotensin II 
into conscious unstressed animals and changes in plasma 
concentration and urinary excretion of a major 
metabolite of PGI2 were monitored. The latter approach 
in particular provides an accurate measure of the rate 
of entry of PGI2 into the circulation (Fitzgerald, 
Brash, Falardeau and Oates 1981) which in man is 
decreased by aspirin therapy (Fitzgerald, Oates, 
Hawiger, Maas, Roberts, Lawson and Brash 1983) and 
increased by stressful procedures such as cardiac 
catheterisation and angiography (Roy, Knapp, Robertson 
and Fitzgerald 1983). 
In the present study, despite infusion of a dose of 
angiotensin II sufficient to cause a mean increase in 
blood pressure of 24 mmHg and decrease in renal blood of 
31% for three hours, there was no change in excretion of 
the metabolite of PGI2 nor a change in its 
concentration in plasma. Moreover, it is highly 
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unlikely that changes in glomerular filtration rate 
altered excretion of the metabolite since there was also 
no change in excretion rate when expressed as a fraction 
of glomerular filtration rate. It is possible that 
infusion of angiotensin II for only three hours might 
cause only a small, but still significant increase in 
PGI2 synthesis which would not be reflected by changes 
in urinary excretion of dinor 6 keto PGF1a. The lack of 
change in plasma concentration of dinor 6 keto PGF1a 
before and after angiotensin II makes this a less likely 
explanation. Another possibility is that PGI2 released 
in response to angiotensin II in the vasculature is 
metabolised differently than PGI2 formed in the systemic 
circulation (Brash, Jackson,Saggesse, Lawson and 
Fitzgerald 1983), in which case dinor 6 keto PGF1a 
might not be the most appropriate metabolite to measure. 
Recently it has been shown that dinor 6 keto PGF1a 
consistutes only a small proportion of total PGI2 
metabolites in plasma (Taylor, Shebuski and Sun 1983). 
However after systemic infusion of PGI2, the size and 
time course of the increase in plasma concentration of 
dinor 6 keto PGF1a was similar to that for another 
metabolite of PGI2, dinor 6,15 diketo PGF1a, suggesting 
that both compounds provide suitable measures of entry 
of PGI2 into the circulation. Indeed this confirms the 
findings of Fitzgerald et al (1981) that urinary dinor 6 
keto PGF1a and dinor 6,15 diketo PGF1a equally reflect 
changes in entry of PGI2 into the systemic circulation. 
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The observation that angiotensin II increases 6 keto 
PGF1a and dinor 6 keto PGF1a in plasma is therefore in 
contrast with the presently described finding of no 
change in plasma and urinary of dinor 6 keto PGF1a 
(Machleidt, Forstermann, Anhut and Hertting 1981). The 
increases were transient however and had returned to 
control within one hour of the infusion. The simplest 
explanation for these discrepancies is that angiotensin 
II does stimulate an immediate increase in PGI2 
synthesis (within 2 minutes) but that this is not 
sustained; this small transient increase not being 
detected by the later urine and plasma measurements used 
in the present study. The real point at issue however 
is whether PGI2 antagonises the systemic vasoconstrictor 
activity of angiotensin II. Whilst this may be the case 
in the early period after angiotensin II infusion the 
absence of change in urine and plasma dinor 6 keto PGF1a 
suggests that this is not a significant factor within 30 
minutes of any increase in angiotensin II concentration. 
The results also do not exclude the possible stimulation 
by angiotensin II of PGI2 synthesis within the renal 
vasculature. Such PGI2 synthesis maybe measured better 
by monitoring urinary excretion of 6 keto PGF1a, the 
stable hydrolysis product of PGI2 (Rosenkranz, Kitajima 
and Frolich 1981; Patrono , Pugliese, Ciabattoni, 
Patrignani, Maseri, Chierchia, Peskar, Cinotti, 
Simonetti and Pierucci 1982; Wilson, Loadholt, Privitera 
and Halushka 1982) rather than the dinor derivative 
produced by systemic metabolism of PGI2. 
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Despite the substantial effects of this dose of 
angiotensin II on systemic and renal haemodynamics, 
there was no apparent stimulation of systemic PGI2 
synthesis. Acute elevations of angiotensin II in sodium 
replete subjects, for example during changes in posture 
(Brown, Davis, Lever, McPherson and Robertson 1966) are 
therefore unlikely to be modulated by increased systemic 
PGI2 synthesis. Although angiotensin II may stimulate 
the synthesis of some other prostaglandins, the apparent 
resistance to the vasopressor effects of angiotensin II 
may be best accounted for by changes in position of the 
dose response curve for angiotensin II. If dose 
response curves are constructed for the effects of 
angiotensin II on blood pressure as a function of the 
plasma concentration of angiotensin II, under certain 
circumstances then changes in response may be entirely 
accounted for by changes in position of the dose 
response curve, and the associated release of a 
vasodilator need not be postulated (Bean, Brown, Casals- 
Stenzel, Fraser, Lever, Millar, Morton, Petch, Riegger, 
Robertson and Tree 1979). Such an explanation might 
also explain the apparently increased pressor response 
of normal subjects to angiotensin II during treatment 
with indomethacin (Negus, Tannen and Dunn 1976; 
Speckart, Zia, Zipser and Horton 1977; Vierhapper, 
Waldhaus and Nowotny 1981). In two of these studies 
(Speckart, Zipser and Horton 1977; Vierhapper, Waldhaus 
and Nowotny 1981) plasma renin activity decreased while 
the subjects were on indomethacin, implying that basal 
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synthesis of angiotensin II was also decreased. The 
resulting decreased receptor occupancy by endogenous 
angiotensin II would then result in an increased 
response to the infused compund. 
There is therefore little support for the concept 
that release of PGI2 from the systemic vasculature 
modulates the pressor effects of angiotensin II during 
sodium replete conditions. Are there are any conditions 
under which systemic vascular sensitivity to angiotensin 
II cannot be accounted for by normal dose response 
relationships? One possible condition when this might 
be the case is during the established phase of one clip 
two kidney hypertension. Although the plasma 
concentration of angiotensin II increases shortly after 
partial occlusion of a renal artery (Caravaggi, Bianchi, 
Brown, Lever, Morton, Powell- Jackson, Robertson and 
Semple 1976; Maxwell, Lupu, Viskoper, Aravena and Waks 
1977) it returns towards control within 14 days, despite 
persistence of the hypertension (Watkins, Davis, Hanson, 
Lohmeir and Freeman 1976; Freeman, Davis, Watkins and 
Lohmeir 1977, Lupu, Maxwell and Kaufman 1977). Unless 
there is a substantial increase in the vascular 
sensitivity to angiotensin II, it is unlikely to be 
directly causing the persisting hypertension. The 
observed similarity of the dose response effect of 
infused angiotensin II on blood pressure, in both the 
normotensive and hypertensive groups in the present 
studies, confirms that pressor sensitivity to 
angiotensin II is not increased in the established phase 
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of two kidney one clip hypertension. Circulating 
levels of angiotensin II are therefore likely to be 
insufficient to maintain blood pressure by their direct 
vasconstrictor activity. 
5. Factors determining renal sensitivity to angiotensin 
II 
The response of the kidneys to infused angiotensin 
II was rather different after induction of hypertension. 
The dose related decreases in urine flow, sodium 
excretion, effective renal plasma flow and glomerular 
filtration rate in the normotensive group are similar to 
the changes described in other studies in dogs (Waugh 
1972). In the hypertensive group, despite similar 
increases in blood pressure, urine flow decreased to a 
much smaller extent during infusion of all three doses 
of angiotensin II, indeed during infusion of the 
highest dose there was a small increase in flow. Sodium 
excretion also increased rather than decreased during 
all three infusions in the hypertensive group, and there 
was not the same dose related decrease in either renal 
plasma flow or glomerular filtration rate, as in the 
normotensive groups. Renal clearance studies could only 
be performed on urine obtained from both kidneys. This 
is not a limitation in the normotensive group but in the 
hypertensive group the two kidneys will be very 
different, thus complicating any explanation of the 
observed effects. Divided renal function studies by 
Deforrest, Davis, Freeman, Watkins and Stevens (1975) in 
this model of hypertension suggest that after two weeks 
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the unclamped kidney contributes the greater proportion 
of total renal function, particularly in regard to urine 
flow, sodium excretion and glomerular filtration rate. 
The major part of the changes in observed renal function 
in response to angiotensin II are therefore likely to be 
occurring in the unclamped kidney. 
The decreased response to angiotensin II in the 
hypertensive group could in theory have three 
components. Firstly, there may be receptor 
desensitisation to angiotensin II. Secondly there may 
be indirect tachyphalaxis to angiotensin II, due for 
example to metabolic smooth muscle or neural 
adaptation. Thirdly it may be some consequence of 
clamping, other than the raised level of angiotensin II. 
Explanations of possible receptor desensitisation to 
angiotensin II in the hypertensive group can be derived 
from previous studies of normal animals under varying 
conditions of sodium balance. Resistance to the effects 
of infused angiotensin II in sodium depleted rats when 
the plasma concentration of endogenous angiotensin II is 
increased, may be the result of increased receptor 
occupancy by endogenous angiotensin II (Thurston and 
Laragh 1975; Cowley and Lohmeir 1977),or alternatively 
there may be a decrease in the actual number of 
receptors or their affinity for angiotensin II 
(Strewler, Hinrichs, Guiod and Hollenberg 1972; Aguilera 
and Catt 1981). Previous studies in rat suggest that 
renin is depleted in the untouched kidney of the one 
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clip, two kidney model (Brunner, Desaulles, Regoli and 
Gross 1962; Huang, Ploth, Bell, Work and Navar 1 981 ). 
Intra -renal angiotensin II levels may not however be 
depressed to the same extent (Mendelsohn 1980). 
Moreover captopril increased renal blood flow in the 
untouched kidney of hypertensive dogs (Zimmerman, 
Mommsen and Kraft 1980) and rats (Huang, Ploth, Bell, 
Work and Navar 1981), suggesting that angiotensin II 
levels maybe higher than predicted. If this was indeed 
the case then the relative resistence to the 
vasoconstrictor effects of angiotensin II could be 
caused by any one of these potential changes in receptor 
function. 
The angiotensin II induced natriuresis might reflect 
a direct tubular action of angiotensin II, since its 
effect on tubular sodium reabsorption is dose dependent 
(Harris and Young 1977). It is well known that 
increases in systemic blood pressure can cause a 
pressure natriuresis (Guyton, Coleman, Cowley, Scheel, 
Manning and Norman 1972). The increased pressure as a 
result of angiotensin II infusion in the hypertensive 
animals might then increase renal perfusion pressure to 
a level sufficient to induce a natriuresis, even if 
there was no difference between normotensive and 
hypertensive kidneys. This is unlikely since the level 
of blood pressure in the normotensive animals during 
infusion of 15 ng /min /kg body weight angiotensin II was 
similar to the pressure in hypertensive animals during 
infusion of 5 ng /min /kg body weight and yet very 
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different effects were observed on renal function. 
Persisting hypertension might impair renal 
autoregulation such that a rise in perfusion pressure, 
as a result of angiotensin II infusion, will cause a 
larger increase in renal blood flow. The decrease in 
tubular sodium reabsorption as a result of the increase 
in renal blood flow might then be sufficient to exceed 
other antinatriuretic effects of angiotensin II and 
result in an overall increase in sodium excretion. 
An entirely different explanation would be that 
release of vasodilator compounds such as prostaglandins 
is increased in the hypertensive state and that they 
partially antagonise the effects of angiotensin II in 
the kidney. Infusion of angiotensin II into the kidney 
of anaesthetised animals (McGiff 1970) and into the 
systemic circulation of conscious man (Frolich, Wilson, 
Sweetman, Smigel, Nies, Carr, Watson and Oates 1975) 
results in increased synthesis of PGE2. Its local 
release therefore may modulate the vasoconstrictor 
action of angiotensin II. Indeed angiotensin II is a 
more potent renal vasoconstrictor if infused into the 
kidneys of anaesthetised dogs when prostaglandin 
synthesis has been inhibited (Aiken and Vane 1973). 
Although renal PGE release probably increases 
transiently after partial occlusion of one renal artery 
(Dighe, Smith, Ungar and Whelpdale 1978) it returns to 
control values within 8 days. Inhibition of 
prostaglandin synthesis at this time does not result in 
significant changes in blood flow of the untouched 
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kidney (Zimmerman 1978). However, in the present study, 
there was a significant increase in renal PGE release as 
reflected in urinary PGE excretion, within 14 days of 
the development of hypertension. It is possible that 
this enhanced renal PGE synthesis occurs in the clipped 
kidney, but the histological studies described in this 
thesis suggest that the untouched kidney maybe more 
active than the clipped kidney in this respect. 
Enhanced PGE synthesis within this kidney would provide 
an explanation for the decreased sensitivity to 
angiotensin II and explain the results obtained. The 
renal synthesis of prostaglandins other thanPGE2, and 
thromboxanes, may also be altered in this model of 
hypertension, and therefore use of prostaglandin 
synthetase inhibitors may not provide a useful means of 
defining the particular role of PGE2. Future 
availability of selective antagonists of PGE2 is likely 
to provide a more specific approach. Some studies have 
however demonstrated exacerbation of hypertension by 
long term treatment with prostaglandin synthetase 
inhibitors supporting the possibility of a general or 
renal vasodilator role for some prostaglandins 
(Pugsley, Beilin and Peto 1975; Romero and Strong 1977). 
The ultimate explanation for the altered renal 
response to angiotensin II in the hypertensive state is 
probably a combination of effects. Whilst changes in 
receptor numbers, occupancy or affinity maybe important 
in mediating the decreased renal sensitivity to 
angiotensin II, increased systemic blood pressure and 
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enhanced release of vasodilator prostaglandins may also 
have a role. 
6. The renomedullary interstitial cells 
The morphological studies of renal medullary 
interstitial cell granules provide an alternative 
approach for assessing possible roles for the kidney in 
modulating blood pressure. The physiological 
significance of the granules in these cells is unclear, 
but their anatomical localisation suggests that they are 
well placed to have an important role in the regulation 
of nephron function. 
They appear able to synthesise collagen and ground 
substances, (Osvaldo and Latta 1966) which will directly 
influence the osmotic environment of the medullary 
papilla. As discussed previously, the cells also have 
the capacity to produce large quantities of 
prostaglandin (Muirhead, Germain, Leach, Pitcock, 
Stephenson, Brooks, Brosius, Daniels and Kinman 1972). 
Many studies have commented on the presence of dark 
osmiophilic granules in the interstitial cells, and it 
has been demonstrated that the number of such granules 
per interstitial cell is altered under a variety of 
different conditions. Fluid deprivation or dietary salt 
restriction causes a decrease in the numbers of dark 
granules in the interstitial cells (Nissen 1968a; Nissen 
1968b; Osvaldo and Latta 1969). In both spontaneously 
hypertensive and deoxycorticosterone acetate treated 
salt loaded hypertensive rats, the granule count per 
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intersitial cell is decreased compared with the count in 
cells from normal rat kidneys (Muehrcke, Mandel, 
Epstein and Volini 1969; Tobian, Ishii and Duke 1969; 
Mandai, Frolich, Chrysant, Pfeffer, Yunice and Nordquist 
19714). In rats with hypertension induced by partial 
occlusion of one renal artery, the granule count is also 
decreased in both kidneys, although more so in the 
untouched kidney (Ishii and Tobian 1969). In contrast 
the present data from studies on dog kidneys show a 
significant decrease in the total number of granules per 
interstitial cell in the untouched kidney, but in 
kidneys with a partially occluded renal artery a very 
marked increase in interstitial cell granularity 
compared with normal and untouched kidneys. An inverse 
relationship between the numbers of dark granules and 
the degree of hypertension has been claimed (Tobian, 
Ischii and Duke 1969; Ischii and Tobian 1969) whereas 
the results of this study and those of other workers 
(Muehrcke, Mandai, Epstein and Volini 1969) do not 
provide support for such a correlation. Species 
differences may partly explain these differences, but it 
is also possible that the changes in granule count per 
interstitial cell are not a true reflection of the total 
number of granules in the medulla. Variations in the 
numbers of interstitial cells under different conditions 
may be as important as the changes in granule counts per 
cell. The overall number of interstitial cells cannot 
be quantitified by the present techniques. 
In the dog kidney the light and dark granules in the 
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interstitial cells appeared to be quite distinct 
morphological entities. The large proportion of dark 
granules in the clamped kidneys (95.3 %) is in direct 
contrast to the small proportion in the untouched 
kidneys (31.1 %). The actual number of light granules 
per cell in the untouched kidneys is larger than in both 
the clamped kidneys and normal. It is impossible to 
determine from this study whether there is any 
structural relationship between light and dark granules. 
The inverse change in number of dark and light granules 
in the clamped and untouched kidneys might suggest that 
dark granules transform into light granules, becoming 
larger in the process, and that this process is enhanced 
in the untouched kidneys. The secretory function of the 
interstitial cell is controversial (Mandai, Frolich, 
Chrysant, Pfeffer, Yunice and Nordquist 1974; Bohman and 
Jensen 1976); however, both types of granule have been 
observed when being extruded from the cell, suggesting 
that the contents of each are secreted separately. The 
electron microscopic appearances would suggest that the 
lipid content of the dark granule is greater than that 
of the light granule. 
Increased granularity of interstitial cells in 
hydronephrotic kidneys (Cornai, Farber and Paulsrud 1975) 
is accompanied by an increased capacity for 
prostaglandin synthesis in response to a variety of 
stimuli (Nishikawa, Morrison and Needleman 1977). The 
lipid content of interstitial cells mainly consists of 
triglyceride, containing a high proportion of 
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arachidonic acid (Cornai, Farber and Paulsrud 1975; 
Nissen and Bojesen 1969). Although this may represent a 
store of prostaglandin precursor (Cornai, Prose, Farber 
and Paulsrud 1974; Vogt 1978) fatty acid precursors of 
prostaglandin synthesis are thought to be released from 
phospholipids (Vogt 1978) and not triglycerides. 
It is therefore unclear whether the granule count 
bears any direct relation to prostaglandin synthesis. 
However the presence of large numbers of light granules 
in the untouched kidney may relate to an increased 
capapcity for prostaglandin synthesis under certain 
circumstances. 
To summarise, there is little evidence from direct 
infusion studies of angiotensin II to support the 
concept that prostaglandins (particularly PGE2 and PGI2) 
modulate its systemic vasoconstrictor activity. The 
results of the morphological study of interstitial cell 
granules are consistent with the possibility that a 
lipid material may modulate the renal vasoconstrictor 
response to angiotensin II particularly in the untouched 
kidney. Indeed the angiotensin II infusion studies 
suggest that PGE2 is a potential candidiate, and that 
its release in response to angiotensin II is enchanced 
under stressful conditions, such as after the 
development of hypertension. To examine this question 
further and at the same time provide more information on 
the relationship between prostaglandin synthesis, sodium 
balance and renin release a number of studies were 
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undertaken in man. 
7. Prostaglandinsi sodium and renin release in man 
Prostaglandins have been implicated as an integral 
component in the mechanism of renin release resulting 
from stimulation of both renal baroreceptors(Data, 
Gerber, Crump, Frolich, Hollifield and Nies 1978) and 
the macula densa (Gerber, Nies and Olsen 1981). Studies 
in the isolated perfused hog kidney indicate that PGI2 
stimulates the release of both active and inactive renin 
(Ohde, Ogilhara, Nakamaru, Higaki, Gotoh, Masuo, 
Ohtsuka, Saeki and Kumahara 1982). This suggests that 
PGI2 maybe the endogenous prostanoid responsible for 
renin release. This hypothesis is supported by the 
observation that renal artery constriction in the B- 
adrenergically blocked dog induces concomitant increases 
in both renin and renal secretion of 6 keto PGF1a, the 
hydrolysis product of PGI2 (Jackson, Gerkens, Brash and 
Branch 1982). Thus, sodium deprivation, which increases 
renin by a prostaglandin mediated mechanism (Frolich, 
Hollifield, Michelakis, Vesper, Wilson, Shand, Seyberth, 
Frolich and Oates 1979) might be associated with an 
increase in PGI2 biosynthesis. During the study on 
sodium deprivation in normal volunteers described in 
this thesis, there was a substantial increase in plasma 
renin activity and yet there was at the same time a 
reduction in urinary excretion of dinor 6 keto PGF1a* 
These results do not support the hypothesis linking 
PGI2 synthesis and renin release. Furthermore 
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the levels of plasma renin activity increased in the 
patients with Conn's syndrome after removal of the 
aldosterone secreting adenoma and yet the urinary 
excretion of dinor 6 keto PGF1a again moved in the 
opposite direction and decreased. 
The direct infusion of angiotensin II in animals 
failed to increase PGI2 synthesis. Stimulation of 
endogenous angiotensin II synthesis both by dietary 
restriction of sodium in normal subjects, and by removal 
of the adenoma in patients with Conn's syndrome, 
provided an alternative means of addressing the same 
questions. In each instance the urinary excretion of 
dinor 6 keto PGF1a moved in the direction opposite to 
that expected if angiotensin II was indeed a major 
determinant of PGI2 synthesis. A possibility that 
cannot completely be excluded is that subtle changes in 
renal function may have altered dinor 6 keto PGF1a 
excretion. Although metabolite concentrations were 
corrected for creatinine excretion, renal function was 
not measured directly in the normal subjects, however, 
changes in creatinine clearance post- operatively were 
not marked, and the slight decrement in the glomerular 
filtration rate bore no relationship to the decrement in 
urinary dinor 6 keto PGF1a excretion. Metabolite 
excretion is unlikely to be altered by changes in serum 
potassium resulting from removal of the adenomas, as 
urinary dinor 6 keto PGF1a excretion was normal in 
patients with Bartter's syndrome and remain unaltered 
during administration of a potassium load (Watson, Gill, 
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Branch, Oates and Brash 1983). 
An alternative explanation for the changes in urinary 
dinor 6 keto PGF1a excretion is that they are directly 
reflective of alterations in extracellular fluid volume 
status. Removal of aldosterone secreting tumours and 
keeping normal subjects on a low sodium intake are both 
manoeuvers that are associated with contraction of the 
extracellular fluid volume (Perera and Blood 1946; 
Biglieri and Forsham 1961). Under these conditions it 
is possible that changes in endogenous PGI2 synthesis 
reflect alterations in vascular tone secondary to those 
in extracellular fluid volume. 
There are two comparatively simple methods of 
effectively expanding extracellular fluid volume; either 
by intravenous infusion of isotonic sodium chloride 
solution, or by immersing subjects up to the neck in a 
water bath. Both methods provide a means of assessing 
the role of prostaglandins in mediating the response to 
effective extracellular fluid volume expansion. It has 
been reported that during water immersion urinary 
excretion of PGE increases in parallel with that of 
sodium in both sodium loaded and sodium depleted 
subjects. However pretreatment with indomethacin 
inhibited the increase in sodium excretion only in 
sodium depleted subjects, despite a decrease in PGE in 
both groups (Epstein, Lifschitz, Hoffman and Stein 
1979). Renal plasma flow was not measured in these 
studies. In a previous study in which normal subjects 
received an infusion of sodium chloride solution, a 
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significant decrease in urinary PGE excretion was 
observed after the infusion (Kramer, Prior, Stinnesbeck, 
Backer, Eden and Dusing 1980). It was also found that 
indomethacin given before and during the infusion of 
sodium chloride inhibited the increase in renal plasma 
flow. 
The results of the study reported here show that 
effective renal plasma flow was significantly decreased 
by indomethacin throughout, providing further evidence 
for the importance of prostaglandins in modulating renal 
vascular tone, at least under these conditions (Stein 
and Fadem 1980). However the acute increase in 
effective renal plasma flow observed during the sodium 
chloride infusion was not affected by prostaglandin 
inhibition. In addition to the observed effects of 
indomethacin on effective renal plasma flow there was 
also, in contrast with the study by Kramer et al 
(Kramer, Prior, Stinnesbeck, Backer, Eden and Dusing 
1980), a small inhibitory effect on the increment in 
sodium excretion that occurred in the period following 
completion of the sodium chloride infusion. 
The different results obtained in these studies may 
have arisen as a result of either the different 
techniques used to induce natriuresis, or the different 
doses of indomethacin employed. In some studies larger 
doses of indomethacin were given than in the present 
study, but even then complete inhibition of 
prostaglandin synthesis, as indicated by absence of PGE 
in the urine, was never achieved (Epstein, Liftschitz, 
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Hoffman and Stein 1979; Kramer, Prior, Stinnesbeck, 
Backer, Eden and Dusing 1980). 
Decreased urinary PGE excretion during the sodium 
chloride infusion suggests that PGE is not directly 
involved in mediating the increase in sodium excretion 
and indeed may be exerting an antinatriuretic effect. 
It is very unlikely however that PGE within the urinary 
space has any direct effect on sodium excretion since 
micropuncture studies indicate that PGE2 must act on the 
serosal surface of the tubule if it is to influence 
sodium excretion (Fine and Trizna 1977; Stokes and Kokko 
1977). In view of the multiplicity of sites of PGE 
synthesis in the kidney it is therefore possible that 
urinary PGE is not a good measure of PGE that is 
exerting an effect on sodium excretion within the 
kidney. Chronic increases in sodium intake increased 
the rate of conversion of PGE2 to PGF2a via PGE2 9 
ketoreductase (Weber,Larsson and Scherer 1977). The 
effect of acute infusion of sodium chloride on this 
enzyme system has not been examined but such changes 
might account for the observed decrease in urinary PGE 
excretion. 
The apparent increase in urinary PGE excretion during 
water immersion remains difficult to reconcile with the 
results of the sodium chloride studies. These immersion 
studies have however been repeated recently and the 
results suggest that, at least in sodium replete 
subjects, there is no change in urinary PGE excretion 
(O'Hare, Roland, Watson, Dalton, Brimble, Chapman, 
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Bhoola and Corrall 1985). 
Indomethacin has many effects other than inhibition 
of prostaglandin synthesis (Flower 1974). Indeed, as 
has already been pointed out, inhibition of 
prostaglandin synthetase, even when specific, may affect 
flux through the lipoxygenase pathway. None the less, in 
the absence of more specific compounds it does permit 
some conclusions to be drawn about the relative role of 
prostaglandins. Indomethacin treatment before the 
sodium chloride infusion caused a small inhibition in 
the subsequent rate of sodium excretion and a decrease 
in renal plasma flow. The inhibition of sodium 
excretion may be a result of inhibition of a direct 
effect of prostaglandins on tubular sodium reabsorption, 
but it is more likely to be a consequence of the 
decrease in renal plasma flow, which may result in 
changes in physical forces acting across the proximal 
tubule (Earley and Friedler 1965). Alternatively, it 
could be a result of an intrarenal redistribution of 
blood flow that has been noted previously in animals 
after prostaglandin inhibition (Kirshenbaum, White, 
Stein and Ferris 1974; Beilin and Bhattacharya 1977). 
Intravenous infusion of large volumes of sodium 
chloride solution will cause an early transient 
expansion of the vascular volume, after which the sodium 
chloride solution will diffuse into the interstitial 
space. Urinary excretion of dinor 6 keto PGF1a 
transiently increased during the sodium chloride 
infusion suggesting that systemic PGI2 synthesis was 
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also increased. The source of the increased PGI2 
synthesis can only be speculated, but studies of the 
portal vasculature during portal hypertension indicate 
that venous distension may be sufficient to stimulate 
PGI2 synthesis (Hamilton, Rosza and Hutton 1981; 
Hamilton, Phing, Hutton, Dandona and Hobbs 1982). This 
may be a purely passive phenomenon of little functional 
significance, or alternatively it may be an important 
mechanism dilating capacitance vessels to accomodate 
changes in vascular filling pressures. It is even 
possible that the increased PGI2 synthesis may have a 
role in causing the dilatation of the renal vasculature 
and the observed increase in effective renal plasma 
flow. 
8. Conclusions 
Investigation of the role of prostaglandins in 
controlling the systemic vasculature and renal function 
has not proven to be easy. Prostaglandins primarily 
function as local hormones. The presently available 
methods of analysis provide comparatively poor means of 
measuring local changes in prostaglandins, particularly 
with respect to kidneys. The difficulties are 
compounded by the multiple potential actions of 
prostaglandins, depending on their site of synthesis 
within the kidney. The use of inhibitors of their 
synthesis is an attractive experimental tool but is 
limited by the multiple effects of the presently used 
non -steroidal anti -inflammatory drugs. Despite these 
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limitations, work in the last decade has greatly 
improved our knowledge of the role of prostaglandins in 
blood pressure control and renal function. The further 
refinement of analytical techniques combined with the 
availablility of more specific inhibitors andselective 
antagonists will lead to further improvements in our 
understanding over the next decade. 
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